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Genomic research and databases came into prominence following the large- 
scale scientific research and investments into human genetics in the 1990s. Genome-
based knowledge, which promises new diagnostic and therapeutic techniques,  also 
produces political, economic, ethical, social, and regulatory dilemmas. The thesis 
examines the governmental, techno-scientific, and economic power-relations lodged 
in genomic research. The thesis focuses on Iceland and Newfoundland and Labrador 
as the cases, which attracted venture capital investments and research because  
genetically homogenous populations are ideal for conducting genetic research to 
detect the roots of the diseases. With a Foucauldian lens, the power relations between 
the subjects including, biotechnology and pharmaceutical companies, venture 
capitalists, patients’ groups, and state, are analyzed in parallel with neoliberal 
governance model. Biotechnology companies, investors, and governments play 
significant roles for supporting the biotech industry. Discourses of rational self-interest 
and personal responsibility are deployed, in particular cases national identity and 
ethnic pride are also articulated with the emphasis on the rational self. These 
discourses mask not only ethical concerns, but also power relations between the 
parties. The comparison of the governance alternatives in these two cases tries to offer 
insights regarding neoliberal governance model, which mobilizes individual conduct in 
line with political economic ends.  
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CHAPTER ONE- INTRODUCTION 
1.1) Overview 
This thesis project will explore genomic research and the associated 
governance mechanisms with a focus on knowledge and expertise in the life sciences. 
The governance mechanisms emerged in the context of the neoliberal political 
economy and affected the field of genomics, a bourgeoning section of the 
biotechnology industry. The governance realm is informed by techno-scientific 
developments and political and economic factors, and as the thesis argues, which  
results in alternative governmentalities. The thesis analyzes the governmental, techno-
scientific, and economic power-relations lodged in genomic research and new 
medicine grounded in genome-based knowledge. In this research, the act of 
governance will not be limited to the state as a single actor. Using a Foucauldian lens, 
the thesis examines the complex webs of power relations between the subjects 
including, biotechnology and pharmaceutical companies, venture capitalists, and 
patients’ groups, as well as state agency. This multifactorial trajectory helps to 
illuminate the emergence and functioning of genomics within the neoliberal model. It 
also assists in covering issues, such as the genetic reductionism, the commodification 
of health knowledge, and the formation of the new group and individual identities 
situated between health and illness.  
Personalized or precision medicine is a new approach that promises to re-
engineer and transform life with early interventions and treatments designed according 
to the genetic characteristics of individuals. Personalized medicine is a set of 
“treatments targeted to the needs of individual patients on the basis of genetic, 
biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient 





2229). In this sense, individually tailored medicine, which relies on genetic research to 
detect the individual differences of patients at the molecular level, might help improve 
the efficiency of medicine to cope with numerous diseases. However, scientific 
discoveries facilitate the manipulation and transfer of human genetic material (Rose, 
2007). Genome-based knowledge, this thesis shows, produces political, economic, 
ethical, social, and regulatory issues. 
Genomics and personalized medicine have been subjects of debates to improve 
healthcare outcomes. For instance, Ricciardi and Boccia (2017, p. 36) claim that 
personalized medicine is a path for sustainable healthcare, which requires a radical 
shift in medicine towards disease prevention and early diagnosis and relies on a more 
participatory model of empowered citizens. The promissory discoveries in genomics 
and the application delay in health care practices increased the calls for actions on the 
governance mechanisms that facilitate this field. According to Khoury et al. (2011, p. 
487), a broad-based approach to human genomics through multilevel interventions, 
including policy change, clinical–public health partnerships, and consumer and 
provider education, should be deployed for the gap between the scientific discoveries 
and healthcare outcomes. Knoppers et al. (2010, p. 225) support the access of 
governments and researchers to genomic databases, as well as the construction of 
those biobanks with public funding to integrate genetic knowledge into healthcare 
effectively. 
This thesis focuses on Iceland and Newfoundland and Labrador (NL) because 
their alternative governance models bring light to political, economic, ethical, social, 
and regulatory controversies. Even if these governance models are inconsistent and 
not entirely effective, they provide researchers with valuable sources to analyze policy-





such as national norms in Iceland and redistributive justice in NL. The entrepreneurial 
model and provincial approval model developed in Iceland and NL respectively have 
influenced additional attempts to construct genetic databases throughout the world, in 
particular in the UK.  
The biobank projects, both in these cases and in other parts of the world, are 
contemporary strategies of biopolitics to govern life. As Gottweis (2008, p. 25) points 
out, ”body surveillance in the context of the developments of contemporary life 
sciences means something distinctly different than in earlier time, with respect to 
surveillance, with respect to bodies, and with respect to the shaping of the 
infrastructure of surveillance and monitoring- the shaping of the structure and the 
organization of institutions of monitoring bodies and population.” In this sense, the case 
study analysis of this research explains how biotechnology companies, venture capital 
investors, and governments support the biotech industry, including biobanks. I argue 
that biotech supporters deploy the discourses of rational self-interest, personal 
responsibility, and self-care. In addition, national identity and ethnic pride are also 
articulated with the emphasis on the rational self. These discourses mask not only 
ethical concerns, most notably the potential violation of patient privacy, the impossibility 
of obtaining meaningful consent given the inherently communal nature of genes, and 
genetic determinist trend in medicine with respect to the roots of illness, but also power 
relations between the parties involved.   
The comparison of the cases will offer crucial insights into the functioning of the 
neoliberal governance model. The neoliberal governance model mobilizes individual 
conduct in line with political-economic ends. This model also aims to manage the 
tensions associated with private enterprises and national values. Within the context of 





the articulation of nationalistic discourses with the global economic targets through the 
neoliberal governance model are analyzed. Through the articulation of local and global 
dimensions under neoliberal governance, the mobilization of individuals towards a 
specific reference point is realized.   
An appropriate policy response, amid the different conceptions and debates on 
genomic research, is crucial for the future of healthcare. In this sense, this thesis will 
examine the governance mechanisms for the regulation of genomic research, the 
translation of knowledge, which is generated through these scientific activities, and the 
adaption of precision medicine into health practices. In so doing, the governance 
mechanisms in the cases examined and the capacity of the governance alternatives to 
address political, economic, ethical, social, and regulatory issues will be discussed in 
this thesis. 
1.2) Literature Review  
Genome-based knowledge and technologies produce complex governance 
mechanisms and have health policy implications that have yet to be fully explored by 
the literature in social sciences. The shifts in medical knowledge, healthcare, and 
regulatory framework as a result of genomics and genetic databases represent a 
radical transformation that requires a comprehensive perspective. However, the 
literature on genomics concentrates on particular subjects and processes with a limited 
scope, therefore resulting in a gap in the literature.  The ethical debates on the informed 
consent mechanism, the governmentality analysis of genomics with a focus on 
molecularization of life and politics (Rose, 2007), and the microphysics of power 
relations, and the new concepts of the social studies of science and technology (STS) 
scholars about the subjectification and knowledge production processes bear these 





The scholarship on ethical issues is constructed on the principle of individual 
autonomy in parallel with the neoliberal economic model. The debates of “the right to 
know versus the right not to know” (Chadwick et al. 1997) and “rights and 
responsibilities in the face of genetic knowledge” (Rhodes, 2002) can be exemplified 
as the focus on the autonomous rational subject excluding the subjectification and 
power relations (Bunton & Petersen, 2005, p. 13). Indeed, Chadwick et al. (1997, pp. 
19-20) claim that autonomous individuals can reasonably decide on genetic testing on 
the grounds of the right to know if they are genetically susceptible to specific conditions 
according to whole-genome sequencing or other predictive measurements. Rhodes 
(2002, p. 420) has a similar position about individual autonomy when she questions 
the responsibilities of individuals to each other regarding genetic knowledge. The 
informed consent mechanism with an emphasis on autonomous subjects is affirmed 
as a primary instrument regarding the research participation as well. For instance, 
McGuire and Beskow (2010, p. 376) suggest a model of consent that relies on 
communication with research participants to honor participants’ altruism and respect 
their autonomy. Knoppers and Chadwick (2005) discuss the emerging trends in the 
ethics of human genetics research, such as reciprocity, mutuality, solidarity, citizenry, 
and universality, marking a communitarian influence on ethics, as well as distributive 
justice debates. The ethical debates can exclude the subjectification processes, in a 
Foucauldian sense, the process through which human beings become subjects, and 
microphysics of power relations, portraying individuals as autonomous rational 
subjects.  
The incorporation of governmentality analysis into genomic research and 
associated problems produced better analyses that did not ignore the subjectification 





administer individuals in an uncoercive way, paving the path for the analysis of power 
relations beyond the realm of state and oppression. Miller and Rose (1993), using 
Bruno Latour’s notion of action at a distance, illustrate how political authorities combine 
personal conduct with socio-political objectives. For example, economic growth is 
governed via experts and expert knowledge. Neoliberal governmentality comprises of 
indirect mechanisms and techniques which entangles the personal conduct of 
individuals with political-economic targets; at the same time, individuals are convinced 
that their conduct is aligned with their own self-interest. These narratives filled the gap 
in ethical debates that presuppose individuals as autonomous subjects. The inclusion 
of the actors to make a governmentality analysis beyond the state mechanism 
undoubtedly provides better insight. However, as Jessop (2011) criticizes, Anglo-
Foucauldian école, such as Burchell, Gordon, and Miller (1991), Miller and Rose 
(2008), exclude the function of state mechanism while managing the inclusion of the 
micro-physics of power into the analysis.  
The state undertakes a central role under the neoliberal model. This role is not 
in parallel with an understanding of the state as an entity outside of social and 
economic production. However, instead of state mechanisms and the normative choice 
between the public and private initiatives, the alternative objects of analyses are also 
developed in a Foucauldian vein. For instance, Valverde (2016, pp. 212-13) focuses 
on the governance networks beyond the binary public and private distinction and 
claims that the ad hoc hybrid governance mechanisms are not a mere result of 
neoliberalism that existed before it. The power is not fixed and not limited to the political 
domain. However, her “post-institutional perspective” provides minimal insight into the 
shift in the rationality of political power as a result of neoliberalism and the construction 





observe today is not a reduction of state sovereignty and planning capacities but a 
displacement from formal to informal techniques of government and the appearance of 
new actors on the scene of government “(Lemke, 2007, p. 57). As such, an analysis of 
genomics that takes non-state actors into consideration will help better apprehension 
of the phenomena. However, the state mechanism that undertakes new and crucial 
functions under neoliberalism should not be ignored in order to render a theoretical 
perspective insightful as far as possible.   
Among STS  scholars, there is an interest in genomics as well. These scholars 
attempted to define developments in this field with new terminology and narratives, 
mostly with new concepts as well. In some cases, these efforts to explain the 
transformation of knowledge production in life sciences created the vagueness about 
the content of the concepts. For instance, Rajan (2006) combines a Marxist account of 
economic terms with the Foucauldian narrative of biopolitics to develop the biocapital 
terminology. Rajan (2006, p. 4). traces “a mutual constitution of the scientific and the 
social as a coproduction” while investigating the development of novel biological 
sciences in cooperation with political regimes. This research offers some helpful 
insights, such as the connection between the subjectification and value. However, his 
arguments lack the basis to define biocapital as a new mode of capitalist accumulation, 
even if this new mode is defined as an alteration, not a radical rupture. A rigorous 
account of these new bio-concepts, such as biovalue, biolabour, bioeconomics, 
biocapital, biocommodification, is illustrated by Birch (2017). He criticizes this 
enthusiasm of the scholars of STS to theorize modern biotechnology, life sciences, and 
bioeconomy in a sense which engenders the “fetishization of everything bio-,” thus 
complicating the analysis of the relation between the modern life sciences and 





among STS scholars is likely to create ambiguity inasmuch as the fashion for coining 
new concepts clouds the meaning that they contain. Birch argues, scholars overapply 
Foucauldian biopolitics terminology to analyses of bioscience. 
There are also publications in social sciences on the social implications of new 
technologies in genetics and medicine. Indeed, precision medicine based on genomic 
knowledge, techno-scientific developments, in general, are not value-neutral 
innovations, achievements, or discoveries external to the social body. These 
arguments are supported well within coproduction and socially informed technology 
narratives. Scientific knowledge is a co-production embedded by social discourse and 
contexts (Jasanoff, 2004). Within this context, “specifically desired ends are built into 
the knowledge and techniques of biomedicine, bioscience, and biotechnology, in a 
manner in which technology is socially informed” (Franklin & Lock, 2003, pp. 4-5). 
Rabinow (2005) offers a new term while examining the new genetics, biosociality, as a 
network of identity terms beyond a biological metaphor. “If sociology is culture 
constructed on the basis of a metaphor of nature, in this new form, nature will be 
modeled on culture understood as practice. Nature will be known and remade through 
technique and will be finally become artificial, just as culture becomes neutral” 
(Rabinow, 2005, pp. 186). Biosociality represents the formation of the new group and 
individual identities situated between health and illness, such as carriers of genetic 
susceptibilities. The concept of biosociality also explains how new groups and identities 
are formed around new concepts of diseases. However, beyond the analysis of micro-
power, anatomo-politics at the molecular level, and the biopolitics concentrating on the 
molecular level (Rose, 2007), the factors at the macro level that impact the global mass 






Genomics is a set of techno-scientific practices; it also functions socially and 
culturally to interpret and transform human bodies. The extension of medical 
interventions into life, which becomes a major institution of social control and a new 
repository of truth, had been previously discussed (Zola, 1972), before the era of 
genomic discoveries. Biotechnological developments have been, however, technical 
means to facilitate both further diffusions of medicine into everyday life practices and 
redefining the normal through new preventive approach in the healthcare that focused 
on individual genomes. Clarke et al. (2003, p. 163) claim that “medicine as a politico-
economic institution and sociocultural good grew” which transforms knowledge 
production and human bodies co-producing technoscience and social forms together. 
The literature regarding how medicine plays a role in shaping perceptions about life is 
a limited scope as compared to the Foucauldian lens, which offers a more complicated 
portrait of the role of medicine (Lupton, 1997). However, critiques on the capacity of 
new genetics to create alternative discourses can be combined with the Foucauldian 
governmentality perspective to illustrate how these discourses mask coercion.  
In Foucauldian terminology, the analysis of micro-power is not limiting in terms 
of scale to exclude a macro analysis; it is a point of view, a methodological approach 
(Foucault et al., 2008, p. 186). The factors, such as the global dominance of 
neoliberalism, articulation of political-economic grounds, constitute the conditions 
through which the biotechnology industry and techno-scientific developments in 
medicine emerge. Therefore, these factors at the macro level and transformation of 
state under the neoliberal model as a vital factor of the facilitator of new economic 
activities should be included in the analysis of emerging sectors of the knowledge 
economy, including genomics. As Jessop indicates (2011, pp. 60-61), Foucault 





of society but also studied how specific governmental practices and regimes were 
articulated into broader economic and political projects. 
In sum, there is a gap within the literature on the analyses of genome-based 
knowledge and governance of genomics. The ethical debates associated with genomic 
research are constrained with the informed consent mechanism, which relies on 
rational subjects, individual autonomy, and empowerment discourses. The attempts to 
integrate governmentality to the analysis of genomics successfully illustrate the 
microphysics of power relations, whereas the emphasis on the “political power beyond 
state“ (Rose & Miller, 2010), which underestimates the role of state mechanisms, limits 
the depth of the analyses. The extension of medical and genetic concepts into daily life 
practices, defined as medicalization (Zola, 1972), biomedicalization (Clarke et al., 
2003), the formation of new identities called biosociality (Rabinow, 1992), and the co-
production of scientific knowledge (Jasanoff, 2004) provide insights abut the 
subjectification processes. However, these theoretical approaches are not sufficient to 
cover the transformations as a result of genome-based knowledge through which the 
biological existence is reconceptualized in social and political-economic contexts. 
1.3)  Theoretical perspective 
In this thesis, a theoretical perspective that aims to integrate the micro and 
macro level of analyses is deployed. In this sense, the theoretical perspective 
encompasses the microphysics of power relations and the actors involved in genome-
based knowledge production, and macro-level political relations to include state agent. 
By combining these levels, this thesis examines on a theoretical basis the capacity and 
techniques of the governance mechanisms to produce discourses that mobilize 





A Foucauldian perspective is appealing to analyze the techno-scientific 
developments of the age of the genomics and power relations between the subjects 
because it provides a more robust analysis of the techniques for control over the 
biological existence of individual bodies and population, at micro and macro levels, and 
subjectification processes for governable bodies. From this point of view, the human 
body is not outside medical discourse and practices. On the contrary, “the biological 
existence of the human subjects, body and its various parts are constructed through 
discourses and practices, through the clinical gaze exerted by medical practitioners” 
(Lupton, 1997, p. 195). 
Dynamics of power are complex and associated with several interwoven and 
contextual factors, contrary to the premises of the classical model of sovereignty in 
which power and knowledge are external to each other, by reducing power to 
domination and repression, which is not able to reflect the multiplicity of power relations 
(Foucault, 2003). Foucault offers an alternative theory for the genealogy of relations of 
power than the classical theory of sovereignty. In fact, power always relies not upon 
coercion, but discourses in which individuals feel that they pursue satisfactions, such 
as happiness and wellness. Truth and power are not external to each other; modern 
power is able to mask itself by producing alternative discourses (Dreyfus & Rabinow, 
1983). Turner (1997) states medicine is accepted as legitimate in everyday life through 
this capability of masking despite its disciplining function. Foucauldian analysis has a 
great competency to reveal the discourses that mask the coercive features embedded 
in the empowered subject of neoliberalism and new genetics promising novel solutions 
in medicine. The numerous and diverse techniques used to intensify genomics and 
precision medicine serve for the subjugation of bodies and the control of populations 





Foucault’s biopolitics is a pivotal term for this analysis. This notion explains how 
technologies of power function to control life through its two poles, the control of the 
body, labeled ‘anatomo-politics,’ and the control of the species, labeled ‘biopolitics,’ 
operating at the level of the population. “The disciplinary techniques targets individuals 
to create docile bodies under surveillance through institutions like schools, hospitals, 
and armies, whereas regulatory techniques aim at populations as a global mass of 
individual bodies” (Foucault, 2003, p. 241). In close relation with biopolitics is 
governmentality. The meaning of governmentality or the term of government in a 
Foucauldian sense range from governing the self to governing others, “the conduct of 
conducts” that is to say, a form of activity aiming to shape, guide, or affect the conduct 
of some person or persons, the government of one’s self and of others” (Gordon, 1991, 
p. 2). Foucault links governmentality, which is a novel art of government composed of 
new tactics and techniques, to the notion of biopolitics. Governmentality is “the 
ensemble formed by the institutions, procedures, analyses, reflections, the 
calculations, and tactics that allow the exercise of this complex of power, which has as 
its targets population, as its principal form of knowledge political economy, and its 
essential technical means apparatuses of security “(Foucault, 1991, p. 102). Biopolitics 
and governmentality together offer critical insight into expert knowledge and scientific 
discourse around the genetic knowledge and techniques, as well as the governance of 
this space under the rationalities of neoliberal governmentality. 
Personalized medicine and neoliberal policies on health care center ‘patient 
empowerment,’ and as such, it is a pivotal term. According to this notion, patients as 
unconstrained subjects are supposed to become informed participants in research 
projects, administrators, and coordinators of their health data. This patient typology 





assigned in healthcare. Patient empowerment is not consistent with the technologies 
of the self for bodily optimization. For Foucault (1988, p.17), these technologies are 
“practices to transform one’s own body and mind to affect their own bodies and souls, 
thoughts, conduct, for transforming the self to attain happiness, purity, wisdom, 
perfection, or immortality.” The empowered patients seem to resemble the actors in 
the search for self-maximizing as per rational principles in the market rather than those 
practicing technologies of the self. Patients, who are free and active subjects towards 
their personal enhancements as consumers of diagnosis and therapeutic products of 
pharmaceutical and biotechnological industries, are the theoretical foundation at the 
molecular level for the development of medicine based on genotypes.  
Discourses, including patient empowerment, that mask power relations are the 
crucial factors to the conduct of individual conduct in that power does not rely on 
oppression and coercion. “Power is not so much a matter of imposing constraints upon 
citizens as of making up citizens capable of bearing a kind of regulated freedom“ (Rose 
& Miller, 2010, p. 272). In this sense, individuals do not feel themselves oppressed 
while making decisions on their wellness as empowered subjects. However, neoliberal 
governmentality guides them to live the freedom in which individuals discipline and 
regulate themselves through the rights and responsibilities of being rational subjects. 
The “conduct of conduct” explains the manipulation of uncoerced subjects in parallel 
with the targets at the macro level.   
In this sense, empowerment rhetoric turns into a novel form of domination and 
a bipolar subjectification, causing both enhancement and subjugation. Precision 
medicine, aiming to substitute a one-size-fits-all approach, is constructed on the ideal 
of the informed consent to ensure individual autonomy. However, this idealistic 





responsibility of healthcare choices to patients. Reardon (2012, p. 27) points out that 
“twenty-first-century efforts to map and characterize human differences at the genomic 
level present us with a different problem of power and science. This problem  derives 
not from domination, but freedom.” Therefore, exclusion based on genetic determinist 
approach to the roots of diseases and disempowerment emerges as a product of 
practices that are said to free individuals.   
The patient empowerment discourse also ignores health literacy levels, 
differences in the economic resources of patients, and their motivation for participating 
in medical procedures. As Cooper and Waldby (2014) illustrate, poverty is a 
fundamental reason for research participation or donation of biological material for 
those with no alternative access for medical treatment. The way in which public health 
responsibilities are transferred to at-risk individuals by reducing personal differences 
to merely genetic profile might exacerbate healthcare injustices. Additionally, it is highly 
likely that empowered subjects faced with highly sophisticated diagnostics and 
therapies of personalized medicine may not have the ability or expertise to guide their 
care effectively.  
The neoliberal governance model reconfigured the distinction between the 
public and private spheres because of the special position given to the market in social 
organization. Public services are pressured to be more effective and innovative, 
leading to public-private sector collaborations and hybrid governance models. As a 
result, the introduction of market-based solutions in the public sector, especially in 
healthcare, which is not a just a technical issue; on the contrary, a political decision to 
redistribute healthcare responsibilities, changes the concept of healthcare from a 
population-based approach to optimized care in entrepreneurial terms (Scheil‐Adlung, 





This model shapes state mechanisms towards a competitive global economy 
and innovative industries like biotechnology and the ‘competitive state’ (Cerny, 1997). 
The shift in the function of the state mechanism is highly significant because the states 
became agents in the fostering of emerging biotechnology sectors for competition 
purposes. Competitiveness through knowledge-based economies motivated states to 
support the biotechnology sector. Through public funding and flexible regulatory 
regimes, states supported innovative sectors to increase their competitiveness in the 
global economy, as well as the collaborative enterprises with private sector agents. 
Shorett et al. (2003) suggest that developments in biotechnology is an example of the 
successful collaboration of the scientific discovery of the universities and public 
research facilities and product development of the private sector under favorable 
regulatory regimes, most notably University and Small Business Patent Procedures Act 
of 1980 in the USA, known as Bayh Dole Act, creating an active role for citizens as 
investors and consumers. According to the Act, scientific discoveries resulting from 
publicly-funded research can be patented, which represents a milestone for academy-
industry partnerships. In this sense, states maintain global competitiveness through 
the funding of research and development activities through academy-industry 
collaborations, which are supported by advantageous regulatory regimes to protect the 
property rights and patents. “Particularly in the case of the knowledge-driven bio-
industries, this meant a concentration not only on the infrastructures of innovation but 
also on ‘agglomeration and network economies and the mobilization of social as well 
as economic sources of flexibility and entrepreneurialism“ (Salter & Faulkner, 2011, p. 
2). The establishment of national biobanks, which are genetic databases using the 
principle of genetic homogeneity, are also examples of biopolitical projects in 





same time, biobanks have also been conceptualized as a mechanism to promote 
international competitiveness.” 
The neoliberal governance model functions on the basis of the market, which 
functions according to the competition principle rather than the principle of regulation. 
The notion of homo oeconomicus or economic man is a central figure in this setting, 
extending beyond the economic domain to involve all aspects of social life in the 
neoliberal model (Foucault et al., 2008, p. 268). In this sense, neoliberal 
governmentality shapes the personal conduct of individuals on the basis of rational 
choices of empowered subjects in the privatized and marketized health services. 
Larsen and Stone (2015, pp. 946-47) point out that manipulating economic incentives 
becomes a vehicle for directing individual behavior, whether the behavior entails a 
patient’s demand for certain health services or a doctor’s decision to prescribe certain 
treatment. In the entrepreneurial society, individuals are supposed to invest in their 
health as consumers of the products of new medicine based on their genetic 
dispositions, therefore investing in themselves.  
The hybridization of policies is also another feature that develops together with 
the neoliberal model. Based on the blurring of the distinction between public and 
private, hybrid mechanisms result not only in the extension of the “privatized” state 
enterprises into other domains but also new forms of sovereignty (Hibou, 2004, pp. 3-
4). The hybridization can be in the way of utilizing the benefits of economic activities, 
which blossomed with neoliberal policies for redistribution and social policies (Torrado, 
2016, p. 699). In this way, national states and private enterprises that invest in new 
economic sectors are major actors to maintain popular support for the governments 
and economic activities. Transnational agencies can also function in the hybridization 





economic ones. For instance, Dean (1995) analyses the policy change in the income 
support for unemployed people replacing the unemployment benefit scheme with a 
differentiated structure of benefits tailored to fit the particular requirements, which is 
supported by the Organisation for Economic Co-operation and Development (OECD) 
within the context of active society as well. He observes the hybrid nature of the policy 
aiming at various politico-administrative goals and ideals, such as income 
redistribution, alleviation of poverty and disadvantage, equity, efficiency, and social 
justice. These goals involve practices of self-formation, practices concerned to shape 
the attributes, capacities, orientations, and moral conduct of individuals as 
governmental-ethical practices (Dean, 1995, pp. 567-68). In these initiatives, the 
targets of social policies are subdued by the ends to regulate individual conduct 
towards a particular understanding, such as an active society. In this sense, the 
hybridization stands for the extension of the state function through policies conducted 
with private sector partnerships, as well as the growing capacity of the opinion-making 
of this new political-economic setting. 
The techno-scientific developments in biomedicine and precision medicine are 
historical consequences of the political-economic factors accelerating the need for the 
policy alternatives in the health services and promotion. Globalization, the crisis of 
welfare state, and global hegemony of the neoliberal economic model and the 
discourses associated with have affected public health policy and services. 
Neoliberalism, in brief, produces discourses that affect the emergence of genomics as 
a sector and the alternatives of governance at two levels. The first one, at the micro-
level, is the patient empowerment discourse in which empowered individuals search 
for self-maximization in goods and services, including customized public services. 





macroeconomic level. The second one, at the macro level, is the competition state 
discourse in which states play a central role in supporting economic development 
through hybrid governance mechanisms in collaboration with the private sector. As a 
result, public services are reconfigured to maximize output with market principles and 
an entrepreneurship mentality through new techniques and strategies, including the 
calculation of service costs, outsourcing, or service level changes policies.  
A transition to new understanding in medicine and health care delivery, as well 
as the application of new technologies into health practices, became compulsory as a 
result of the global hegemony of the neoliberal economic model.   There was a trend 
in health policy side, which  Gottweis et al., 2009 defined as “global techno-managerial 
paradigm,” focusing on free-market solutions, efficacy, and techno-scientific 
innovations and its application to health practices. The publicly-funded health care 
systems became an extension of the market as technical means for healthcare 
provisions. As Tutton (2016, p. 10) exemplifies, “initiatives such as British 
Government’s introduction of personal health budgets for people with chronic illness 
with the aim of enabling them to customize their own health management” delineates 
how publicly-funded healthcare systems transform under neoliberal policies. In parallel 
with new market-based principles, public services, including health care, became key 
areas for the assimilation of techno-scientific innovation into society.   
Political-economic transformations resulted in the societal impacts and changes 
in knowledge production as well. The significant epistemological shift in medicine and 
the medical gaze emerged as a result of techno-scientific developments in genomics. 
In the nineteenth century, life and corporal existences were conceptualized with normal 
or pathological categories. In a similar vein, the biotechnological developments 





doctor’s expertise on diagnostic gaze. Through this transformation, the diagnostic 
practices of clinicians have been accompanied and partially substituted by novel 
diagnostic techniques, bioinformatic systems used for making statistical predictions, 
and correlations between the patients through genome-based knowledge and 
genealogical information. In this transformation, new value creation processes also 
emerged. “Biovalue refers to the yield of vitality produced by the biotechnical 
reformulation of living processes” (Waldby, 202, p. 310). Rose (2007, p. 11) points out, 
this is the “the molecularization of styles of biomedical thought, judgement and 
intervention” which resulted in the new techniques of medical interventions and the 
economic exploitation of human vitality. This, therefore, creates new fields for the 
expertise in which genome-based diagnostic tools transform the human body into a 
commodity to be exploited economically. The technical means to render human tissues 
transferable at the molecular level contributed to this exploitation. However, the 
political-economic factors, the neoliberal shift in public services towards privatization, 
and the state policies to support high technology sectors under the competitive global 
economy provided the necessary settings to construct an economic domain from 
techno-scientific discoveries. 
The governance alternatives for genomics stand at the nexus of the 
hybridization of policies: the neoliberal policies and the social policies to incorporate 
the research outcomes into healthcare, as well as sharing the benefits as a result of 
population-based research among the community. On the one hand, the idea of the 
reconstruction of public services, including healthcare, and society at all, by reference 
to the market, for-profit investments into genomic research, and mobilization of 
personal conduct as per rational choices motto prevails. On the other hand, an 





public goods (Knoppers et al., 2010, p. 230), in order to maintain science-state 
concordat to maximize the delivery of economic, health, and social benefits, as well as 
the advancement of scientific power (Salter & Salter, 2017, p. 270). How do these ends 
diffuse into governance alternatives for genomics? Are the market-driven and for-public 
benefit understandings able to coexist in the governance mechanisms? Under the 
hybridizing effect of the neoliberal policies and their ability to mask the discourses 
serving for subjectification, it is possible to say that trade-offs between the policy 
alternatives are realized within the boundaries of the neoliberal model and discourses 
associated with. In this sense, the governance alternatives of genomic research 
diversify to the extent that state and transnational agencies apply economic and 
political strategies to biotechnological innovations. 
In brief, as an emergent field within the biotechnology sector, genomics followed 
the path created by the neoliberal economic model. This field was fostered by the 
states in parallel with their new functions under neoliberalism and the growth model 
that relies on knowledge-based economies. In the governance of genomics, the hybrid 
policies that came to prominence with neoliberalism play a central role. This 
hybridization has two interconnected dimensions. The first one is the partnership 
between the public and private as a result of new functions of state. The second one 
is related to the content of policies, which, on the other hand, aim to realize economic 
targets; on the other hand, shape individual conduct through discourses in parallel with 
macro-level ends. The governmentality approach provides an in-depth analysis of the 
changing political rationality, strategy, and techniques, as well as subjectification 
processes. Through this approach, it is possible to examine the governance 
mechanisms regarding genomics and policy trade-offs.  





The method of the thesis is case-study based. This method provides an in-depth 
understanding of phenomena, their constitutive process, and the actors involved, which 
can be used to build and validate a theory (Gagnon,  2010, p. 2).  The case study 
method also has some limitations. It only permits the understanding of a single facet 
that is intrinsic to the case under investigation but studying others, such as the 
comparison between cases, helps moderate this constraint (Hamel et al., 1993, p. 35). 
In this vein, this research focuses on Iceland and the Canadian province of 
Newfoundland and Labrador (NL) as the cases to examine in-depth the genomic 
research projects and governance methods associated with them. In order to deal with 
the limitations of studying peculiar cases and making a microanalysis, an analysis of 
the biotechnology sector on a global scale will also be conducted in this thesis. 
The data used in the thesis relies on three different kinds of sources. The first 
one is a literature review concerning the emergence of the biotechnology sector, 
neoliberal governmentality, and the endeavors in genomics in Iceland and NL. The 
second one is an analysis of policy documents regulating the genomic research 
activities and health policies for both cases, as well as publications by transnational 
organizations on genomic research and precision medicine. The last source is 
fieldwork conducted in Iceland from September to October 2019 to examine the 
Icelandic genome project and the Health Sector Database Act, and more specifically, 
Icelandic genome-based research and knowledge, and the transformation into health 
practices. 
This fieldwork consists of two pillars. The first one is an archival study in the 
National Library of Iceland, in particular, the Timarit database, newspapers, and 
periodicals of the Faroe Islands, Greenland, and Iceland. The second one is interviews 





well as another Icelandic scholar. In these interviews, the application of the knowledge 
generated through the Icelandic genome project and the issues associated with this 
research project, such as privacy concerns, consent mechanisms, and the affordability 
of new discoveries, were questioned.    
1.5)  Case Studies 
The analysis of this thesis dates back to the last decade of the twentieth century 
when large-scale projects to determine the genetic roots of diseases were launched. 
The most prominent initiative was the Human Genome Project, which was operated by 
a broad-spectrum consortium consisting of government offices and scientific 
community and was dependant on pharmaceutical companies for funding. The 
temporal complexity of studying how genome-based knowledge diffuses into society is 
crucial. This complication is not only because the accurate process-tracing on 
genomics can easily turn back to the period what Gottweis (1998, p. 39) “trace the 
politics of molecular biology to its origins in the 1930s”.  In his trajectory, he also 
focuses on the 1950s and 1960s when states started to become involved in governing 
molecules actively through policies, strategies, and institutions. (). It is also a 
consequence of how the way of writing the history of genomics needs an insight into 
the subject that Fortun (2001a) describes as a ‘future anterior.’ This perspective that 
can be summarized with an idiom of “what will have been” represents the promissory 
feature of genomics and its forward-looking statements (Fortun, 2008). As Helmreich 
(2008, p. 468) indicates, “Mike Fortun suggests that understanding the business of 
genomics requires attention to its speculative logic, which he examines by 
demonstrating the role of ‘forward-looking statements’ in generating investment and 
profit”.2008, p. 468). “Genomics companies, like deCODE Genetics, Celera, 





specific regulatory framework of corporate disclosure- a framework that sanctions and 
encourages the promissory quality of the forward-looking information which these 
corporations produce and thrive on” (Fortun, 2012, p. 340).  
Iceland has been at the center of a global debate on genome-based knowledge, 
and NL has a similar position. Both locations are unique because of their relative 
isolation and therefore have great potential for studying the genomic roots of 
complicated disorders (Gibbs, 1998, p. 34; Zhai et al., 2016, p. 1063; Rahman et al., 
2003, p. 167). As a result, global venture-capital has targeted both sites and has 
developed local genome-based research to conduct clinical trials for drug 
development.  
In particular, the case of Iceland’s deCODE Genetics has become known 
worldwide, and its CEO, Kári Stefánsson, turned into an icon of the new genomics 
industry (Gottweis & Petersen, 2008, p. 5). Founded in the USA by Stefansson, a 
neuroscientist at Harvard University, and Jeff Gulcher, deCODE is funded by venture 
capital funds that were willing to invest in the Icelandic gene pool before the start of the 
company’s operations in Iceland. During the preparation phase, deCODE was able to 
make a deal with pharmaceutical giant Hoffman-LaRoche valued at $200 million in 
exchange of collaborative research on Icelandic genetic properties with the aim of drug 
development, which gave the company huge credibility in Iceland, attracting foreign 
investment to country (Árnason & Wells, 2003). deCODE’s public relations used 
nationalist pride rhetoric to show that their contributions were unique and would make 
a revolution in medicine. Árnason and Wells (2003) point out, project’s economic gains 
were expansive according to the company, for example, the employment of skilled 
workers, the reversal of the brain drain, contributions to the Icelandic economy, a 





and the promise of free drugs. As a result, the company was given a license in return 
for a fee to construct the database called as Health Sector Database (HSD) on the 
basis of presumed consents of participants, which means research subjects were 
presumed to give their consents unless they opted out. Pálsson (2008, p. 44) states, 
“a legal and ethical model or framework for such a comprehensive, national project 
was nonexistent before HSD, which was a pioneering enterprise.”    
The Icelandic Genome Project consists of three different elements: healthcare 
data based on medical documents since 1915, genetic information obtained with 
sample collections, and finally, genealogical records dating back to the ninth century 
based on Icelandic sagas, church, and state records. Three different databases, 
“medical, genetic, and genealogical, formed a comprehensive Biogenetic Project” 
(Pálsson & Hardardóttir, 2002, p. 272). deCODE contracted an Icelandic software 
company to create a database called Book of Icelanders, which compiled the records 
from the ninth century and made family connections with the records. This database 
contains “approximately 700.000 records, the majority of people born in Iceland since 
the first Norse settlement in the ninth century “(Pálsson, 2007, p. 70). It is possible to 
combine the genotypic data, which was collected by participants on the basis of 
informed consent through blood samples, with medical information available in HSD. 
The comprehensive database is supported by arguments on efficiency and national 
norms. According to Stefansson and Gulcher (2000), the medical records were already 
accessible to medical service providers, and provisions of HSD on the encryption of 
medical data will establish a more effective system for the protection of privacy. 
Pálsson (2007) also supports this argument exemplifying the Blood Bank and the 
Cancer Registry databases, which record biomedical information of patients dating 





available in public, and the project was able to gain public support because it 
addressed the passion of Icelanders for keeping genealogical records. The rhetoric of 
setting a database, which will protect the gene pool of the country as a national value 
in a way respecting national norms, serves as a tool to mask the neoliberal incentives 
of the project.   
The Iceland project is valuable because of the controversies that arose during 
its implementation. Issues of privacy and consent were raised as the project 
progressed because of opposition to the project. The Association of Icelanders for 
Ethics in Science and Medicine was established by clinicians and academicians in 
reaction to the project. They stated their opinions in media and public debates. During 
these debates, a gap between the Icelandic society and deCODE Genetics became 
suspect, and a critical public had developed, which caused substantial damage to the 
project. The decision of the Icelandic Supreme Court supported the privacy concerns 
in the practice of database, which caused to stop the activities from setting HSD in 
2003.  Even if deCODE Genetics continues its operations, the mistrust of the public to 
the project and the global financial crisis contributed to the bankruptcy of the company. 
The company was purchased by Amgen, a US biotechnology giant, in 2012 and 
is now operated as a wholly-owned Amgen subsidiary. Currently, deCODE launched a 
website whereby Icelandic people can check if they carry BRCA gene mutations 
responsible for breast and ovarian cancer using their national ID numbers. After its 
proposal to contact each carrier of those gene mutations was not approved, deCODE 
publicized information on a website.  According to an article in the Reykjavik Grapevine 
by Demurtas ( 2018), Kári Stefánsson states that the carriers of BRCA gene mutations 
are most likely to, with a likelihood of 86%, get breast or ovarian cancers. The company 





complaints. deCODE has been subject to debates during the efforts to establish HSD 
and continue to do so after because Stefansson opposed the denial of the company’s 
offer to inform mutated BRCA carriers personally.  
The Icelandic genome project is highly influential in the debates about genomics 
and endeavors for other databases because the Icelandic case has several unique 
features. It is the first and most contentious database initiative. The Health Sector 
Database is the first act in the world regulating the genomics field as well. The 
controversial points are basically caused by the consent mechanism according to 
which the project operated.  For Kaye (2004, p. 117), “ the main objection to the 
Icelandic population collection was that informed consent the internationally agreed 
standard for biomedical research was not sought.” The presumed consent mechanism 
and controversies associated with, such as privacy and the protection of individually 
identifiable data, were discussed at national and global levels. In this sense,  “inspired 
by the Icelandic project,  but also learning from the controversies that surrounded it, 
two further proposals for large genetic databases followed in Britain and Estonia” “ 
(Corrigan & Tutton, 2004, p. 4). 
The story of genomic research in NL begins with researchers from the Baylor 
College of Medicine in Texas who came to Grand Falls in 1998 and collected DNA 
samples from the local people and family histories within the context of their research 
on Arrhythmogenic Right Ventricular Dysplasia (ARVD) which is a heart muscle 
disease known as Newfoundland curse between the local people causing sudden heart 
attacks. This research was not well received, and the researchers were called Texas 
Vampires by locals. According to the article on CBC News, the family members 





blood samples. However, the research was not shared, and the researchers had a 
responsibility to do so.  
The researcher’s breach of ethics prompted NL to examine human genetic 
research in the province. In this context, the provincial government hired Dr. Skanes 
to write a report in 2000.  The same year, a local dermatologist Wayne Gulliver 
convinced Gemini, a British genomics company, which merged with US biotech firm 
Sequenom in 2001 to launch Newfound Genomics (Taubes, 2001). According to the 
Policy Implications of Commercial Human Genetic Research in Newfoundland and 
Labrador Report (2003, p. 13), Dr. Gulliver took part in a research conducted by 
Celltech, a California based biopharmaceutical company, regarding psoriasis in 
Newfoundland and Labrador. During this research, he also advocated for the storage 
of DNA samples collected by local people in the province after a dispute with the 
Celltech that denied the demand of Gulliver. The mission of Newfound Genomics was 
to study the genes of the island’s population using much the same approach as 
deCODE has popularized in Iceland. Nevertheless, Newfound Genomics did not 
succeed and ceased its operations because of government pressure on the company 
after the loans given to the company has become a source of public controversy. 
During the tenure of Health and Community Services Minister Steve Kent, who 
was a member of the Progressive Conservatives, in 2015, the provincial government 
and Sequence Bio, a local company specializing in the use of genetics for the discovery 
of new drugs and therapies, signed an agreement for recruiting 100,000 people in the 
province to analyze “genomic and phenotypic” information. The agreement also had a 
partnership with Genospace, a company based in the USA. The officials of Genospace 
stated that the “Newfoundland and Labrador population is a unique resource for 





highlights its historical isolation and genomic capacity, which parallels with the 
experience of Iceland, which was transformed into a genetic laboratory via a public-
private initiative. Sequence Bio launched Newfoundland Genome Project in 2019 with 
an emphasis on its contribution to the local economy after receiving the approval of the 
province’s Health Research Ethics Board.  
1.6)  Outline of the thesis 
In chapter 2, the global scale content of genomics as a new techno-knowledge 
and new governance model will be discussed. In this context, Human Genome Project 
and the related issues such as public-private research distinction, academy-industry 
collaborations, shifts in the regulatory regime, investments of venture companies into 
biotechnology, and global political developments which constitute the conditions for the 
emergence of biomedicine will be detailed. 
In chapter 3, the thesis examines the Icelandic Genome Project and the 
entrepreneurial model that shaped the governance of the project. This chapter is 
constructed on the data which was collected through fieldwork in Iceland from 
September 2019 to October 2019.  
Chapter 4 explores genomic research activities in Newfoundland and Labrador 
and its governance of research. In this context, policy documents regulating genetic 
research, the operations of past and current genomic research companies, and the 
provincial ethics approval model are examined. 
   Chapter 5 explores the governance and policy options for balancing scientific 
discoveries and commercial interests in order to translate genome-based knowledge 






CHAPTER TWO- GLOBAL PERSPECTIVE 
2.1) Overview 
This chapter will show how biotechnology emerged as a pivotal sector in the 
global economy and was supported with investments in techno-scientific research 
activities. According to Rajan (2006, p. 5), ”biotechnology industry came about largely 
as a consequence of this technoscientific development in 1973 by Herbert Boyer and 
Stanley Cohen”. (Rajan, 2006, p. 5). However, the political-economic factors that 
facilitate new fields of economic activity and turn scientific discoveries into 
technological products are much more multifaceted than a single innovation of 
laboratory production. Along with scientific breakthroughs in DNA research, the 1970s 
also marked a turbulent period of the global economy. This decade marked an 
important political-economic transition characterized by the Organization of the 
Petroleum Exporting Countries (OPEC)oil crisis, the collapse of the Bretton Woods 
System, a financial fixation of global US hegemony, and critiques on the Keynesian 
welfare state. This transition is followed by the neoliberal revolution that came into 
existence, most notably through the economic policies of Thatcher and Reagan 
governments aiming at deregulation and privatization and international free trade in the 
1980s and 1990s in the UK and the US (Helleiner, 2015, p. 88).  A robust analysis of 
techno-scientific activity and the emergence of biotechnology as a sector requires a 
political economy approach because neoliberalism as a dominant political-economic 
model produces new economic activities and subjectification processes in parallel with 
the discourses. 
 Neoliberal policies changed the understanding of the factors of production and 
redesigned economic processes. In the production cycles, neoliberalism matches with 





decrease in the profitability of manufacturing industries in the 1970s. Unlike the Fordist 
production model grounded on mass production, the post-Fordist model is based on 
the principle of flexibility and flexible deployment of inputs in the production processes 
(Jessop, 1993). The composition of labor became a set of “polyvalent skilled workers 
and the service class” instead of the semi-skilled workers who were subsidized with 
the wages, including welfare adjustments in the Fordist period of mass production 
(Jessop, 1991, p. 144). As a result, the re-organization of the labor force in bourgeoning 
sectors on the basis of flexible working schemes and decrease in the number of 
manufacturing industries weakens the power of trade unions as a mechanism for full-
employment through collective bargaining in the Keynesian period.  
The post-Fordist system altered the traditional roles assigned to the household: 
namely breadwinner husbands and caretaker wives. The participation of women in the 
labor force, who were unpaid caretakers of the Fordist era, blurred the boundaries 
between the reproductive and productive spheres of life by integrating private space of 
family, including activities like biological reproduction, into the market (Cooper & 
Waldby, 2014, p. 5). However, gendered working conditions and wage gaps are 
indicators that the intrinsically coercive terms of the workplace follow the oppression of 
women within the family. In this sense, the subordination of women’s labor resembles 
the disciplining function of the family. In terms of the ethos of this thesis, the genetic 
test targeting women to detect breast and ovarian cancers functions in a similar way 
to shape the everyday practices of women.  Through the post-Fordist model of 
production, neoliberalism succeeded in the modification of the dynamics of the labor 
force and the industrial production and paved the way for more efficient new sectors to 
invest in. In so doing, strategies of neoliberal administration diminished the role of semi-





was a reduction in the cost of production, with a new focus on skilled workers and 
flexible work contracts and participation of women the labor force to expand the 
influence of the market into private spheres. In this sense, the extension of market into 
private spheres could be fully completed with the participation of women into labor 
force, therefore resulting in the reconfiguration of family as an institution on the basis 
of market logic. This transformation also represents a shift from the disciplinary to 
regulatory mechanisms, while the subordination of women continues. 
2.2) Biotechnology as a new sector 
The transformation of the state under the neoliberal model is a pivotal factor that 
affects the development of the biotechnology sector, including genomics. The state 
intervention into macroeconomics was one of the prominent features of the Keynesian 
model to support a nation’s targets of full-employment and welfare. However, the end 
of the postwar boom and the oil crisis in the 1970s increased the level of critiques on 
the Keynesian welfare state model revisiting classical liberal writings. The neoliberal 
solutions gained salience during debates on remedies for the crisis of the oversized 
and inefficient state mechanism as a result. Jessop (1993) argues that the theories of 
Austrian political economist Joseph Schumpeter are the most influential ones during 
the transformation of the Keynesian welfare state into what he calls as Schumpeterian 
workfare state. Jessop (1993, p. 9) summarizes distinctive features of this new model 
as: “the promotion of product, process, organizational, and market innovation; the 
enhancement of the structural competitiveness of open economies mainly through 
supply-side intervention; and the subordination of social policy to the demands of labor 
market flexibility and structural competitiveness.” Of these characteristics, 
competitiveness is a new concept that theorists of the state started to adopt in that 





constellation that does not have any competitor even if it intervenes in the market for 
macroeconomic ends. In this sense, Cerny names new state mechanism as 
competition state, detailing it: “as a state to promote a favorable investment climate for 
transnational capital, by providing a circumscribed range of goods and immobile factors 
of capital, including human capital, infrastructure, support for a critical mass of research 
and development activities; essential public services and maintenance of a public 
policy environment favorable to investment “(Cerny, 1995, p. 611). The competition 
state functions within a new domain of collective action in a global theatre since the 
rise of neoliberalism, together with Thatcher and Reagan administrations, also marks 
the shifts from national economies to the global economy. As Jessop (2007b, p. 187) 
points out, the emerging global “political-economic system represents a “new spatio-
temporal-fix, a new social arrangement and socially-constructed institutional 
frameworks for the deferral of contradictions and crisis inherent in capitalism.” The 
states are still significant figures of political economy with their new positions to foster 
investments and new growth sectors and mobilize sources for a competition at the 
global level even if they are forced to retreat services as they had in the Keynesian 
welfare state. 
In theory, the neoliberal political-economic system represents not only a 
particular regime of accumulation in the capitalist system, but it also involves an 
extension of market relations into the social world and its orders at the global level. The 
harmonies of both economic and non-economic factors are required to aim for 
establishing and sustaining global competitiveness. According to Jessop (2007b, p. 
187) growth of new technologies based on the systems of innovation depends on 
“mobilizing social as well as economic sources of flexibility and entrepreneurialism, to 





the extra-economic, micro-social aspects of the political economy that Jessop and Sum 
(2001) further extend it to the cultural political-economy provides a more in-depth 
analysis of the transformation of the state and the interdependence between the 
economic and social terrains. This analysis can be used in further analysis of how a 
hegemonic bloc is created through the mobilization of the social forces in a Gramscian 
perspective. It is also helpful to investigate micro-physics of power between the 
subjects. However, Cerny (2006, p. 685) disagrees and claims that whereas Jessop 
emphasizes non-Marxist theories that privilege socio-political variables, especially 
politically instituted market mechanisms, his most important arguments are still in line 
with economic determinism because of his adherence to Marxist theory. Hay (2004, p. 
40), in a parallel vein, postulates that a new state regime of residual and competition 
state has theoretical advantages in terms of clarity and simplicity than Jessop’s 
Schumpeterian workfare state theory. In fact, theories regarding the interrelatedness 
of social and economic forces can be deployed for more accurate analysis instead of 
avoiding them because of the fear of economic determinism and Marxist Orthodoxy.   
Benefiting from Marxist terminology, not being an exponent of this theory,  is 
Robert Cox, for instance, who points out that a historical structure is a picture of a 
particular configuration of forces, which are material capabilities, ideas, and 
institutions. There is a reciprocal and interactive relationship between them (Cox, 1981, 
p. 136). Cox accepts that ideas are the products of historical conditions, which seem 
at first sight that his evaluation is similar to that of Marxism about the illusive concept 
of the ideology. There is, however, an explicit nuance between Marxist terminology and 
Cox’s formulation in that Marx in The German Ideology describes ideology with the 
“camera obscura” simile, which is an upside-down vision of reality (McLellan, 1995, 





inverted image of social reality, which is distorted and false, whereas Cox merely 
accepts its conditionality as a result of objective social and historical conditions. 
Theoretically, unorthodox approaches that respond to the complexity of the factors 
affecting the changes in the world order can be articulated with Marxist terminology, 
thus resulting in a robust analysis instead of an economic determinist one. 
The economic rationale behind biotechnology is closely related to how 
proponents of neoliberalism understand economic growth and locate technology-
intensive new sectors as a catalyst to reach macroeconomic targets. Rooted in the 
searches for the remedies for the slowdown in the economic growth and concerns for 
a global recession, a new techno-economic paradigm has emerged. Nielsen (1991, p. 
18) describes it as “a cluster of innovations, which involves completely new forms of 
work, new models of management, new locational patterns, and new high growth 
sectors.” Based on this paradigm, technoscience and economic growth gained special 
status as crucial factors for the creation of national pride as well (Gottweis, 1998, p. 
160). New domains grounded on new technologies for economic growth and new value 
creation emphasize the requirement for techno-scientific efforts to exploit the resources 
further to be used for the novel sectors. However, the scarcity of natural resources, 
such as minerals and fossil fuels, which have already come to the point that they are 
not reliable for sustainable growth, makes it impossible to set a future on resources 
that you are able to find naturally. In this sense, the artificial re-creation of nature 
(Rabinow, 2005), by ending the distinction between nature-nurture, provides a reliable 
basis to create an economic activity on biotechnology.  
As a new sector, biotechnology stands at the intersection of techno-scientific 
activities of molecular biology and initiatives to produce biological commodities, in other 





(Kenney, 1998, p. 131). Biotechnological innovations in agricultural production and 
biomedicine then represent tangible examples of this new economic setting. In this 
setting, new domains for economic value creation are constructed to realize the 
economic growth in more sustainable manners, as is the case in biotechnology, which 
remodels nature in a more perfect form. 
Genomic sciences and biotechnology as a source of sustainable economic 
growth is less dependant on its technological capabilities for the discovery of new 
diagnostic and therapeutic techniques than the transferability of its discoveries into 
financial returns in the market. In this sense, cost management has become a crucial 
part of these new industries to ensure financial returns through knowledge production. 
Cooke (2002, p. 5) argues that “to the extent, genomics give rise to superior tests or 
drugs to those presently available at a comparable cost, knowledge is acting on 
knowledge itself to enhance productivity.” However, the issue of affordability of 
genomic diagnostic and therapeutic tools is not a prerequisite itself for the market 
success of these medical products. Genomic pharmaceuticals are less likely to be 
affordable than conventional medications. Rather the crucial point is to assign value to 
novel medical products and convince potential customers about their superiority to 
existing products in the market. This is more urgent because the application of genomic 
techniques in health care practices is quite primitive (Khoury et al., 2011). The 
knowledge on which genomic diagnostic and therapeutic techniques depend is more 
valuable than the results of the application of these tools into medical practices. The 
constitution of the biotechnology sector, in an economic sense, beyond techno-
scientific activities conducted at the universities, includes institutional ends to set a 
market and a function of the transformability of techno-scientific activities into 





of fictitious commodity with reference to Polanyi’s (1957) original conceptualization of 
labor, land, and money as fictitious on the ground that they cannot be defined as 
commodities in essence even if they are exchanged in the market. 
2.3)  The development of genomics and governance mechanisms 
The spatial reconfiguration of economic activity at the global level and new high 
technology sectors that are designed to increase the competitiveness of the nations to 
benefit from the global economy altered the political-economic scene. The publicly-
funded initiatives were invested in new technologies under the conditions of 
globalization and the dominance of the neoliberal model. As a result, there was fierce 
competition among states to reap the benefits of new knowledge economies (Salter & 
Faulkner, 2011). There were general changes and the emergence of novel 
technologies in the various industries within the realm of biotechnology, therefore 
creating the question of the governance of these activities at states and transnational 
agencies level. However, the scope of this research will be limited to genomics and the 
new pharmaceutical industry associated with it.  
Launched in 1990 and completed in 2003, administered by the US Department 
of Energy’s (DOE) and the National Institutes of Health (NIH), Human Genome Project 
(HGP) is a publicly-funded research project to map human genes, which comprises an 
exact example of the investment into competitive economic sectors According to 
Cantor (1990, p. 49), the origin of the project dates back to a meeting in Alta, Utah, in 
1984, where scientists questioned the possibility of sequencing human genomes, 
whereas the DOE has a congressional mandate to investigate inherited damage 
caused by low-level exposure to radiation. DeLisi (1988, p. 489), then the director of 
the DOE Health and Environmental Research programs and avid proponent of the 





“industry, academia, and the national laboratories assessed of the technical feasibility 
of sequencing the human genome, the probable cost, and the potential benefits to the 
nation.” As can be seen in the emphasis in the last passage, in these technical 
meetings in the participatory phase of the project, cost, and returns of the sequencing 
human genes were also debated in addition to scientific points. These debates on the 
cost of the project and potential benefits for the US economy also constituted the 
market logic of genomics part of biotechnology. After the discussions, the project was 
launched with 3-billion-dollar federal funding. Fortun (2008, pp. 51-4) argues that the 
main goal and underlying logic of the HGP are not to fully sequence human genomes, 
holy grails of human genetics, rather to create an infrastructure for more efficient 
genomic technologies to be used in medicine and pharmaceutical industry for 
diagnosis and treatment options. He states that a US-centered genomic economy that 
would be dominant in a competitive global bioeconomy was one of the pivotal reasons 
for federal spending on the project.  
After completion of the research, the economic impacts generated through the 
project went well beyond the scientific discoveries during the research. According to a 
report prepared by Tripp and Grueber (2011, p. 15) for the Battelle Memorial Institute, 
a private science and technology development company headquartered in the USA, 
“whereas the federal government invested $3.8 billion in the HGP through its 
completion in 2003, the human genome sequencing projects, associated research and 
industry activity—directly and indirectly—generated an economic impact of $796 
billion, personal income exceeding $244 billion, and 3.8 million job‐years of 
employment between 1988 and 2010”. The updated figures on Battelle’s website were 
published on 12 June 2013. According to the new report called the Impact of Genomics 





economic growth with a $965 billion in impact, more than 53,000 direct genomics-
related jobs and $293 billion in personal income, leveraged from a total federal 
research and development investment of $14.5 billion from 1988 through 2012”. In the 
last instance, the HGP paved the way for the new projects of genetic research and the 
primary settings of the pharmacogenomics sector. The further initiatives were 
facilitated by the technical means and understanding in parallel with the HGP that 
conceptualizes the human biological material as a new kind of commodity to be 
processed for the generation of more value through public and private agencies. In this 
sense, the HGP goes beyond being a mere scientific project with humanitarian 
purposes to fight against hereditary cancers and complicated disorders. 
Global competitiveness in the biotechnology sector dominated the HGP since 
its start. The competition in biotechnology involved new players in addition to the 
states. Economic competitiveness in knowledge-based technologies was required to 
support the biotechnological revolution through the foundation of new companies. The 
start-up biotechnology companies, located in San Francisco Bay Area, Delaware-
Maryland region, and Massachusetts, were funded increasingly by venture capitalists 
because of the expectations of high return from the emerging US biotechnology sector 
in the 1990s. Newly biotechnology companies like Human Genome Sequences Inc., 
established in 1992 in Maryland, Incyte, established in 1991 in San Francisco Bay 
Area, and Millennium Pharmaceuticals, established in 1993 in Cambridge, 
Massachusetts, managed to develop innovative models using bioinformatic systems to 
mine genetic information and to get profit through a partnership with pharmaceutical 
sector giants like Pfizer, Hoffmann-La Roche, Glaxo (Fortun, 2008, pp. 40-41). In that 
period, several biotechnology companies diversifying their area of operations have 





companies like Applied Biosystems of Foster City, California, and DuPont, of 
Wilmington, Delaware, focused on automated sequencers (Ackerman, 1988, p. 18). 
Among new investments in the biotechnology, the most prominent one was the Celera 
Genomics, founded in 1998 by Craig Venter, who previously attempted to patent the 
stretches of DNA while working for the NIH (Rabinow, 2009, p. 85). Celera Genomics 
challenged the HGP by developing its genome sequencing project because the 
opportunities to patent the discoveries within the HGP were limited. However, while 
approaching the completion of the HGP, then US President Bill Clinton succeed in 
negotiating Venter with the administrators of the public project, therefore ensuring the 
full collaboration of the parties. Venture capital and public-funded investments in 
biotechnology companies help the US maintain its dominance in the competitive global 
economy as discussed and planned before the HGP. 
The global competition and the dominance of the US in the emerging 
biotechnology sector encouraged the other nations to follow the American experience 
as a model in order to compete or at least collaborate with the US, aiming at benefitting 
from new technologies. As Fortun (2008, pp. 36-37)  exemplifies Jack McConnell’s 
statement, who helped draft the early US legislation on the HGP as an officer of the 
pharmaceutical company Johnson & Johnson, about the HGP and its targets. For him, 
the primary target of the project was to support the US biotechnology and 
pharmaceutical industry, therefore keeping America competitive rather than 
understanding the genetic code of humanity. In this sense, the US model for the 
competitive advantage in biotechnology is an example of the mobilization of the 
sources and actors for the desired end. The timely investment into sustained 





academia, and flexible regulatory environment enabling the patenting of the 
discoveries of genomic research together with academia-industry collaboration.  
The public expenditure to support the biotechnology sector in the USA 
generated a multiplier effect, which enables this sector to extend further into global 
markets. Indeed, the European Community attempted to create world class 
competitors in R&D-intensive, high value-added, and high growth sectors targeting 
areas of information technology; manufacturing technology; telecommunications; 
biotechnology; new materials; and marine science and technology (Jessop, 1993, pp. 
22-23). However, the technological expertise of the US in biotechnology, their 
competitive advantage forced European biotechnology companies and European 
Community agencies to establish strategic alliances with US companies. For instance, 
The European Steering Group (ESG) was established in 2014 within European 
Community European Innovation Partnership on Active and Healthy Ageing, bringing 
together representatives from the policy environment and civil society, healthcare 
professionals and scientific societies, academics, and industry; the group that searches 
for sustainable health programs for European people was, however, technologically 
supported by AbbVie, an American publicly-traded biopharmaceutical company, as a 
partner of the project. Birch (2006, p. 95) points out that huge US federal funding on 
biotechnology investment is an important factor for the global success of American 
biotechnology companies in the sector. In turn, the European pharmaceutical 
companies collaborated with US companies instead of national biotech firms in their 
home countries.  
The mythical status of the US biotechnology sector that Gottweis (1998, p. 159) 
observes also has consequences on the regulation of the sector. The regulatory 





as The Bayh–Dole Act or Patent and Trademark Law Amendments Act, which was 
adopted in 1980, motivates the EU to pass similar laws to keep their competitiveness. 
Birch (2006, p. 107) claims that the efforts in other countries, especially in the EU, 
create an impact on the regulatory structure of the other nations toward weaker 
regulatory schemes, thus resulting in a cycle of less strict regulations and more 
competitive capacity. Therefore, the biotechnology sector grows at the global level 
within a discourse of competitiveness and repetition of the development model of the 
American biotechnology sector. 
There is no pure private or public research under the neoliberal model. The shift 
in the role of the state mechanism to foster new innovative sectors and academy-
industry collaborations are the main factors in the hybridization of the research domain. 
In this sense, population-based genetic research and biobank databases are 
associated with the projects that public agencies consider when funding projects. 
These projects need to have a solid financing model and to fit into the national 
innovation system and its characteristics, such as the availability of venture capital or 
the structure of the pharmaceutical industry (Gottweis & Lauss, 2012, p. 66). Deciding 
on the projects as significant expenses of the public budget, the notions with medical 
contents should also be considered within policy-making processes. As a crucial term, 
“clinical utility,” for instance, refers to the likelihood that a given intervention, genetic 
information, will lead to improved health outcome or to whether a test can provide 
information about a diagnosis, treatment, management, or prevention of a disease that 
will be helpful to a consumer (ACMG Board of Directors, 2015, p. 505). In this sense, 
the investment into a genome project is expected to produce a utility in a clinical sense. 
Becker et al. (2011, p. 9) cite the resolution of the European Society of Human Genetics 





in common diseases are likely to be conditional on the environment, while testing for 
these low penetrance susceptibility genes is likely to be of limited clinical utility.” In this 
sense, environmental factors continue to be factors that are not taken into 
consideration in genetic determinist approach to the roots of diseases, whereas this 
approach constrains itself in terms of clinical utility. The research on the genetic roots 
of cancer comprises a significant portion of total genetic research. However, only 5–
10% of all cancers are due to an inherited gene defect. Most cancers are not of 
hereditary origin. Lifestyle factors, such as dietary habits, smoking, alcohol 
consumption, and infections, have a profound influence on their development (Anand 
et al., 2008, p. 2098). The correlation between the disease, environment, and gene 
mutations as a part of clinical utility interwoven with economic value and public budget 
targets, therefore resulting in a severe challenge to policy-making. 
2.4)  Institutional Settings 
The fostering of new high-technology economic domains and investments into 
these sectors were supported by international organizations and governance bodies 
as well. These institutions acknowledged and encouraged investments into knowledge-
based economies as the model for economic growth and supplementary policy targets 
such as sustainable health. The entrepreneurial society is encouraged in this way, 
which is also the social ethic of enterprise that Weber, Sombart, and Schumpeter tried 
to write the political, cultural, and economic history (Foucault et al., 2008, p. 147). The 
global conjecture, the development model, and the aims to incorporate new knowledge 
production into society endorsed by these organizations. New subjectification 
processes are conducted with the diffusion of the social ethic of the enterprise 
(Foucault et al., 2008). As a result, individual conduct is shaped on the basis of the 





The popularity of the knowledge-based economies is related to the revival of the 
Schumpeterian theory in the 1990s and the advocacy of international organizations on 
his arguments. Godin (2006, pp. 17-18) claims that the knowledge-based economy as 
an umbrella concept serves of policy-makers to science and technology issues and to 
their role in the economy. He also adds that this concept owes its salience to efforts of 
the Organisation for Economic Cooperation and Development (OECD). Although his 
definition of the knowledge-based economies as a tool involves minimal insight into 
how the concept of knowledge-economy functions to mobilize social and economic 
forces, his argument about the role of t the Organisation for Economic Co-operation 
and Development (OECD) is quite appropriate. Indeed, neo-Schumpeterians, including 
Freeman and Perez, have been highly influential on the policy-making for industrial 
policies and technology programs, both at national and the level of international 
organizations, mainly the OECD ( Nielsen, 1991, p. 20).  Pyka et al. (2009, p. 5) 
observe that through the efforts of the OECD in the 1990s, Schumpeterian principles 
of innovation and technical change became dominant in the growth policies.  
The OECD publication titled “Knowledge-Based Economy” (1996) has a feature 
of the manifesto about the role of knowledge-economies in the global political economy 
and its function as a solution to the crisis in the 1970s in parallel with the 
Schumpeterian approach. According to this publication (1996, p. 7), the “OECD 
economies should maximize performance and well-being in knowledge-based 
economies for the production, distribution, and use of knowledge and information, in 
parallel with the new growth theory that affects the role of knowledge and technology 
in driving productivity and economic growth.” After the affirmation of the role of the 
knowledge and innovation in economic growth, Knowledge-Based Economy (1996, pp. 





communications, pharmaceuticals, and aerospace. In this sense, investments in these 
sectors have a higher capacity for economic growth and employment with higher 
wages. This model also has social implications beyond economic growth and 
productivity. As per the document (1996, p. 25), “the science system must balance not 
only its roles of knowledge production and transmission but also the transferring of 
knowledge to economic and social actors, enterprises, through the linkages between 
the science system and the private sector to speed knowledge diffusion.“ In this 
framework, the university/industry collaborations and associated economic issues 
such as exclusive licensing, intellectual property rights, equity ownership are the keys 
to diffuse knowledge into society. 
The OECD specifically discussed the future of the bioeconomy in 2009 as well. 
In a publication called “the Bioeconomy to 2030 Designing A Policy Agenda. Main 
Findings and Policy Conclusions” the organization mainly focused on three sectors: 
agriculture, health, and industry. The principle policy conclusions of the document 
regarding health sector emphasize the requirement of translating new technologies into 
health systems, proceeding scientific research on population-based medical research 
through further funding, and enabling the participation of citizens into public dialogues 
to ensure the legitimacy of the scientific efforts. According to the document (2009, p. 
6), “a costly but beneficial revolution in healthcare, some emerging technologies, such 
as regenerative medicine and personalized and preventive medicine, could require far-
reaching changes in healthcare delivery.” The accord of the private sector developing 
health therapies with the public interest, regulatory systems regarding healthcare 
incorporating pharmacogenetics, the support long term research, population-based 
medical databases, and the dialogue with the public on the future benefits of 





The salience of human genomics as a particular branch of the bioeconomy was 
also emphasized by the OECD in “Genomics and The Bioeconomy Symposium” in 
2010. In the event jointly organized by the OECD, the Human Genome Organisation 
(HUGO), the McLaughlin-Rotman Centre for Global Health of the University of Toronto, 
and the Mexican Health Foundation (FUNSALUD), the opportunities of modern 
genomics and the historic achievement in human health in the ten years since the first 
draft sequence of the human genome were discussed. In the conclusion of the 
symposium ( 2010, p. 16),  the development in medicine and biology were described 
as the possibility for humanity to transform health, industry, agriculture, the 
environment as well as the economic status of mankind in general. 
Other international organizations have also been involved in the policy 
suggestion for new knowledge-economies and their application into medicine, such as 
the European Union, the World Economic Forum, and the World Health Organization. 
The European Steering Group (ESG) for Sustainable Healthcare, which was supported 
by the US biopharmaceutical company AbbVie and chaired by Former Health Minister 
of Ireland, Mary Harney, published a pan-European White Paper Acting Together 
Roadmap for Sustainable Healthcare in 2015. During the preparation of this document, 
the ESG met regularly and organized roundtable meetings with high-level policy 
stakeholders at the EU level, including representatives from the European 
Commission, the Council of Ministers, and the European Parliament. The 18 
recommendations put forward by the group focus on three main themes, prevention, 
and early intervention, fostering the empowered and responsible citizen, and re-
organization of care delivery.   
According to the White Paper (2015), the steps for sustainable healthcare are 





and responsibility in citizens and reorganizing care delivery.” To do so, the monitoring 
of the health trends and data collection; the establishing a new data protection rules 
and regulations, the stronger engagement of employers and health professionals in the 
field of occupational health, the tackling with the health illiteracy, and the support of 
new technologies for the transformation of healthcare were also suggested.  In these 
suggestions, besides the protective environment for the biotechnological investments 
into health systems, the rationale of neoliberalism at the individual level, the 
empowerment of individuals was also underlined. Empowerment and tackling health 
literacy are crucial points to create consumers for the products of the 
pharmacogenomics industry that will be integrated into health systems. Underscoring 
individual autonomy conforms with the neoliberal discourse of rational individuals who 
will pursue their biological enhancements with their own choices.  
The emphasis on the requirement to increase health literacy functions as an 
opportunity for the diffusion of the patient empowerment discourse as well. The need 
for education was highlighted within academia and international organizations, pointing 
out different scopes and target groups. For instance, Chapman et al. (2019, 81) 
propose a comprehensive education program that includes the training of teachers, 
doctors and nurses, psychologists, and other professionals on genetics. The World 
Economic Forum Report ( 2013, p. 16) emphasizes the need to improve health literacy 
at every age, starting with schoolchildren, in order to address the change in social 
values and to change how we think about and value health in the age of precision 
medicine. An OECD Report titled Health Literacy for People-Centred Care associates 
health literacy with the ability to make informed decisions about the care options, 





(Moreira, 2018, p.10). In these narratives, the responsibility of education on health 
literacy is articulated within neoliberal discourses as public policy targets.  
The report of another international organization, the World Economic Forum, 
also addresses the problems in the transformation of healthcare. The report prepared 
in collaboration with McKinsey & Company, a global management counseling 
company, titled “Sustainable Health Systems Visions, Strategies, Critical Uncertainties, 
and Scenarios Healthcare Industry” (2013) points out three main actionable points. 
These are “to embrace data and information to transform health and care, to innovate 
healthcare delivery, and to build healthy cities and countries of the future.” In this 
framework, precision medicine as a new technology in medicine, was particularly 
underlined. The World Economic Forum Report also mentioned lifestyle changes as a 
crucial part of living in a healthy way in addition to the requirement for empowered 
individuals, which indicates how new technologies in medicine function as biopolitical 
techniques to shape individual conduct while organizing economic activity under the 
neoliberal model.  
The World Health Organization (WHO), through its publication on its website 
titled “Human Genomics in Global Health,” is another international organization that 
mentioned the technological and scientific innovations in medicine as well. According 
to this publication, these innovations have the potential to influence the standard of 
health of people through genomic techniques in medicine and to contribute to 
economic development through better management of the diseases. In this setting, the 
financing of genetic research, patenting and intellectual property issues, equitable 
access and affordability of genetic information and services, raising the level of public 
awareness on genomics, and ethical standards in genomics were mentioned as the 





for the global collaboration of the effectiveness of new technologies in health practices 
and evaluates the application of these techniques in the emerging economies with a 
global perspective. Whereas Cuba, Brazil, India, China, and South Africa were 
exemplified as the well-functioning examples in the application of genetic technology 
and services to the health needs of their populations, the need for further global 
cooperation through the exchange of the health information was highlighted by the 
WHO. 
2.5)  Conclusion 
 Genomics, as a field of inquiry, and biotechnology, in general, were designed 
as new economic activities in parallel with shifts as a result of the neoliberal model. On 
the one hand, fostering of new high technology sectors by competition states 
accelerated the investments into this sector. On the other hand, the new regulatory 
environment developed synchronically enabled parties involved in research processes 
to patent their scientific discoveries as a result of academy-industry collaborations. The 
biotechnology projects were supported by states with generous funding to create a new 
economic domain for the maintenance of competitiveness. For instance, in the case of 
the HGP, the project aimed at the protection of the US biotechnology and 
pharmaceutical sectors’ dominance in the global political economy. The federal funding 
of the project and the flexible regulation encouraging the property rights on the scientific 
discoveries created proliferated outcomes through the multiplying effects of the initial 
public expenses. In this way, the HGP not only did generate genomics-related 
businesses and employments, and the stock market successes of biotechnology 
companies in the domestic market but also spread these activities to the global 
markets. The perception of the superiority of the US biotechnology sector, which is 





companies, such as the policy-making efforts of the European Steering Group (ESG) 
for Sustainable Healthcare throughout the European Union in collaboration with the US 
biopharmaceutical company AbbVie, while there was fierce competition in the 
biotechnology sector to move forward among the countries The investments into new 
high technology sectors and the development model based on innovative sectors were 
strengthened with the involvement of the international organizations, mainly the OECD, 
in policy and opinion-making processes, by endorsing a knowledge-based economy 
model. 
 The knowledge-based model and similar discourses on entrepreneurship have 
also served as a means to create discourses for social control and regulation. The 
social ethics of enterprise and the role of science and knowledge in economic 
development laid the foundation of the social shifts. Because of new political-economic 
discourse, it is the new field of concomitance that praises the growth and advancement 
of science (Gottweis, 1998, p. 160). In parallel with this Foucauldian argument, the 
analysis of the newly emerged economic activities, domains, institutions, and 
governance alternatives needs to take the discourses producing these into 
consideration. In this sense, the advance of molecular biology, which finally realized its 
full potential in genomics science, was designated to create a science of man for 
consensus formation and cultural hegemony since the efforts of the Rockefeller 
Foundation starting in the 1930s (Kay, 1998, pp. 22-23). The social regulation comes 
into sight with a new form to influence the opinion-making in parallel with the principles 
of the new discourses of political economy. 
The rationale behind biotechnology and genomics, in particular, as new 
economic activities diffuses into individual conduct through discourses. The economic 





innovation and structural competitiveness (Jessop, 1993). After the affirmation of these 
notions as superior values on which the construct discourses, the non-coercive 
character of the neoliberal governmentality produces identities and subjectification 
processes through the discourses. Within the context of genomics and healthcare, 
rational subjects invest in their health as entrepreneurs of their personal 
enhancements. Therapeutic and diagnostic products of new medicine represent the 
innovative aspect of science. It is imperative to pursue new genetics and medicine for 






CHAPTER THREE-THE ICELANDIC GENOME PROJECT 
3.1) Overview 
 This chapter discusses the population-based genomic research in Iceland 
conducted by the private sector company deCODE Genomics. In this context, the 
political-economic circumstances and the legal framework that enables this company 
to mine the Icelandic gene pool for economic benefits are examined. The neoliberal 
economic model is the context for the incorporation of deCODE Genomics to make 
investments in Iceland and the Health Sector Database that set the appropriate 
regulative atmosphere. The entrepreneurial model in the Icelandic genome project was 
implemented by a public-private partnership and managed to articulate individual 
conduct with the targets of the project. In the articulation of the micro-level with the 
project, the discourses of contribution to the local economy and the protection of 
national values, the Icelandic genealogies, and gene pool, through better technological 
means, played crucial roles. 
Iceland was an ideal place to invest because of the combination of genetic 
homogeneity of the population and its public health infrastructure. This combination 
enticed investors and researchers with medical records of the country, which could 
create more accurate pedigrees to examine the roots of the diseases. Together with 
the blood samples collected from Icelandic people during the project and the 
genealogies in Icelandic society dating back to as early as the ninth century, generate 
comprehensive data at the service of the project. The combination of genetic and 
genealogical data generated a great economic value reaped by private-sector 
enterprise and venture capitalist firms. The efforts of the medical experts who were 





database project. In the end, the economic value created from the Icelandic gene pool 
did not any contribution to the local economy as promised, whereas the efforts to 
construct the database turned into a massive biopolitical project. 
The global-level developments are highly decisive in the initiatives for the 
project. On the one hand, a new economic growth model propelled by neoliberal 
policies and governmental bodies encouraged investments in knowledge-driven high 
technology sectors, including biotechnology. On the other hand, a new approach to 
medicine, which focuses on the genetic roots of the diseases, increased the sources 
dedicated to population-based research projects because of the prospected diagnostic 
and therapeutic innovations through genome-based knowledge. In parallel with these 
factors, the launch of the HGP, along with a trend towards personalized medicine, were 
both supported with public funding and then by venture capital investments. As a result, 
new economic activities were created, which fostered further research targeting new 
locales and product development.  
The Icelandic genome project is also a consequence of the local dynamics 
shaped by global economic trends. The 1990s were a turbulent period for the primary 
Icelandic fishing industry. In their collaborative article, the Icelandic anthropologists 
Helgason1 and Pálsson examine the implementation of the systems of individual 
transferable quotas (ITQs). These quotas were first implemented in 1984 following the 
cod wars with the UK and extended further into the Icelandic fishery during the 1990s. 
The ITQs not only represented the commodification of fishing rights, an introduction of 
the market-oriented monetary exchange into the traditional understanding of the 
collective rights over the fish but also created social tensions, such as a national strike 
 
1 Helgason was then employed as the head of the anthropology section in deCODE Genetics in 2000 





of Icelandic fishers protesting against the ITQ system in 1994 (Helgason & Pálsson, 
1997, pp. 452-59).  
The socio-economic disturbances of the fishing industry and the expansion of 
free market economy mechanisms into this isolated island nation in the middle of the 
North Atlantic Ocean generated an impetus to seek alternative ways of value 
production. The global economic trends towards investments in novel biomedicine and 
gene studies and local economic transformations converged in Iceland as genomic 
research. As Rose (2007, p. 150) indicates, Iceland is a site where the logic of new 
biomedicine and new techniques for molecular interventions to generate novel 
relations between life and commerce can be found. Despite this explicit transition in 
the Icelandic economy, Pálsson and Hardardóttir compare the biogenetic databases in 
Iceland with fisheries. In parallel with the importance of fishing for the national 
economy, as a new source of economic growth, the biomedical sector may have 
benefitted from the history of property rights in fishing, which integrate commercial and 
communitarian perspectives, to develop alternative property regimes regarding the 
human genome (Pálsson & Hardardóttir, 2002, p. 285). In this sense, the economic 
benefits through property rights on the Icelandic gene pool are affirmed insofar as an 
equilibrium between the private and public interests is maintained.   
3.2) The saga of deCODE Genetics and the HSD 
 deCODE Genetics is an example of a comprehensive genome project that fits 
the patterns of global venture capital firms targeting genetic studies as new sources of 
high profit. deCODE Genetics Inc. was incorporated in Delaware, the USA, in 1996. As 
a parent company, it owns a subsidiary that fulfills its operations in Iceland, the name 
of which is Islensk erfdagreining ehf., registered in Reykjavik in 1996. According to the 





Commission for the initial public offering of the company on March 8, 2000, the 
cofounders of the company are Kári Stefánsson and Jeffrey Gulcher. Stefansson 
began as the President, Chief Executive Officer, Secretary, and a Director of the 
company in August 1996 and was appointed to serve as the Chairman of the Board of 
Directors in December 1999. Stefansson held a number of positions in academia and 
medical practice, including faculty positions in the Neurology, Neuropathology, and 
Neuroscience Departments at Harvard University and the University of Chicago, and 
the directorship of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. 
Gulcher served as the Vice President of the company responsible for Research and 
Development. Gulcher also had past experiences in the Department of Neurology at 
Beth Israel Hospital in Boston, Massachusetts, and Harvard University Medical School. 
As such, the company was the scientific enterprise of two medical doctors who had 
worked together at Harvard University Medical School and decided to set up a 
company in Delaware because of the favorable tax exemptions. However, a closer look 
at the directors of the company and their affiliations shed light on the crucial features 
of this start-up company.  
 four out of seven venture capitalist companies that invested in deCODE had 
their representatives on the board of directors. Jean-Francois Formela2 has served as 
a director of deCODE since August 1996, and as a member of the Audit Committee 
since February 1998. Formela is a General Partner of Atlas Venture Associates II, L.P.  
Andre Lamotte3 has served as a director of deCODE since August 1996 as a 
 
2 Before joining Atlas Venture in 1993, Dr. Formela was Senior Director, Medical Marketing and Scientific 
Affairs at Schering-Plough in the U.S. where he also held biotechnology licensing and marketing 
responsibilities. 
 
3 In 1989, Dr. Lamotte founded Medical Science Partners, or MSP, which specializes in early stage life 
sciences investments, in affiliation with Harvard University, and has served as the Managing General 
Partner since then. Before founding MSP, Dr. Lamotte served as a General Manager at Pasteur Merieux 





representative of Medical Science Partners. Terrance G. McGuire has served as a 
director of deCODE since August 1996 and as Assistant Secretary since January 1998. 
Since March 1996, he has been a Founding General Partner of Polaris Venture 
Partners, who was a general partner of Alta V Management Partners L.P. Guy P. 
Nohra4 has served as a director of deCODE since August 1996. He is a founder and 
general partner of Alta Partners, a venture capital investing in information technologies 
and life science companies. Despite the professional management team assigned by 
venture capitalists, as Fortun (2008, p. 198) points out, the company itself, and Kári 
Stefánsson individually, emphasize being an Icelandic company. The rhetoric of the 
involvement of local researchers in the project was also deployed in the Newfoundland 
case. However, the Icelandic genome project was portrayed as a contributor to the 
Icelandic identity articulating the project with the nationalist pride on the unique 
Icelandic gene and the tradition of family histories.  
 The initial public offering of deCODE Genetics exhibits the role of the venture 
capitalist through managers affiliated with the venture capital firms in charge since the 
establishment of the company. The method of the financing of the deCODE in the early 
stages makes these relations more obvious. The company was formed with a  $12 
million initial capital funded by seven venture capital firms, which are Advent 
International, Alta California Partners, Arch Venture Partners, Atlas Venture, Falcon 
Technologies, Medical Science Partners, and Polaris Venture Partners (Greely, 2000, 
p.165).  As of 31 December 1999, Alta California Partners and Atlas Venture each hold  
% 7.1 percent of the shares of the company, whereas Polaris Venture holds % 5.7. In 
 
 
4 Prior to founding Alta Partners in 1996, Nohra was a partner of Burr, Egan, Deleage & Co., which he 
joined in 1989 and served as a Vice President from 1989-1997. Previously, Mr. Nohra was a Product 
Manager of Medical Products with Security Pacific Trading Corporation, where he was responsible for 






addition, the representatives of venture capital firms are also stockholders of the 
company by themselves, with the following shares: Formela % 7.1, Lamotte % 2.1, 
Nohra % 7.1,  McGuire % 5.7. There are also Icelandic shareholders of the company 
holding more or less % 1 of the shares of the company. These shareholders are 
Hannes Smarason5, Executive Vice President and Senior Business and Finance 
Officer, Kristjan Erlendsson6, Vice President for Clinical Collaborations, and the Vice 
President of Medical Informatics Sigurethur Bjornsson, who previously served as the 
Chief Executive Officer of an Icelandic investment company. Their presence served to 
strengthen the argument of an Icelandic enterprise investing in Iceland as well. 
 deCODE successfully attracted direct capital investment because of the efforts 
of Kári Stefánsson while he has been working in the USA in the early 1990s. According 
to Zoega, chief psychiatrist of the National University Hospital in Iceland, and 
Andersen, an assistant professor from the School of Medicine at the University of 
California in San Diego, Kári Stefánsson involved in discussions with investors Kevin 
Kinsella. In a letter to Stefansson dated May 16, 1995, Kinsella7 summarizes the idea, 
resulting in the genome project in Iceland: 
As we discussed, Iceland is perhaps the ideal genetic laboratory since there has 
been virtually no immigration (lots of emigration, of course); it is of manageable 
size (200,000+ inhabitants), is an island expected to have many founder effects, 
has high-quality national healthcare-from which we can expect excellent 
disease diagnosis, has formidable genealogies, and the population is 
Caucasian-of most interest to pharmaceutical companies.  
What we would propose to do, in partnership with you, is sponsor a massive 
program to identify probands in the entire Icelandic population, collect blood 
from the entire population, establish pedigrees for important complex genetic 
 
5 Smarason had a background in McKinsey & Co. in Boston as a consultant. 
 
6 Erlendsson is a medical doctor with an educational experience in the USA and the former Director of 
Hospital Affairs at Iceland's Ministry of Health and Social Security before joining the company. 
7 Kinsella, then the became of the president and chief executive officer of Sequena, a genomics company 
operating in La Jolla, California, known for its research on genetic causes of asthma, which was accused 
of "biopiracy" because of the research in Tristan da Cuhna, a small island in the South Atlantic whose 





diseases, genotype members of the pedigrees, conduct linkage studies on the 
disease and positionally clone the genes of interest (Zoega & Andersen, 2000, 
p. 38). 
Prior to the project, there were efforts by the founders of deCODE in order to 
engage with Icelandic patients and research subjects. Hilary Rose (2001a, p. 8) relates 
the origin of the Icelandic genome project to the summer of 1994 when Stefánsson and 
Jeff Gulcher visited Iceland to collaborate in a study of genetic disposition to multiple 
sclerosis (MS) with an Icelandic neurologist, John Benedikz. The link between the 
studies of the duo with Icelandic MS patients and the flow of events towards a 
comprehensive genome project is more meaningful than it seems at first glance. Fortun 
(2001b) points out the Settlement Agreement between the Beth Israel Deaconess 
Medical Center (BIDMC), where Stefansson worked from 1993 to 1996, and deCODE 
Genetics. According to the agreement, Stefánsson's scientific findings of genes 
associated with multiple sclerosis, arrived at by using facilities and resources of BIDMC 
since 1993, would be jointly owned by both parties. The engagement with Icelandic 
patients before the project, regardless of the commercial value of the discoveries of 
the research, enabled the founders of deCODE to mention these studies as tributes to 
the homeland. Sigurdsson (2001, p. 113), who is a historian of science from the 
University of Iceland, indicates that while patients’ groups did not play a large role in 
the Health Sector Database and deCODE controversy and there have been no further 
genetic findings about the MS disease, Stefánsson’s work with the patients in Iceland 
was used to support their claims during the debates about the HSD going forward. 
 In the preparation period to the HSD, deCODE’s effort to obtain financial support 
and, therefore, popularity in Iceland were crucial to achieving the targets of the 
company. The most significant achievement of this period is the certainly research 





Hoffmann-La Roche on February 1, 1998. According to this agreement, Roche and 
deCODE would collaborate to discover genetic variations that affect the pathogenesis 
of diseases and to develop new methods for diagnosing f diseases and drug discovery. 
As stated by the company in the S-1 document, deCODE may receive a total of more 
than $200 million in equity contributions, research funding, and milestone payments. 
This agreement covers research of up to twelve disease categories over a period of up 
to five years. The agreement gives Roche exclusive rights to develop and 
commercialize therapeutic and diagnostic products based on gene discoveries, 
whereas Roche will provide the Icelandic people free of charge with pharmaceutical 
and diagnostics products that emerge from the collaboration. Following the agreement,  
Roche has made capital investments in deCODE, Roche Finance Ltd, or Roche 
Finance, an affiliate of Roche, has purchased shares of Series C preferred stock, has 
also purchased warrants to buy shares of Series C preferred stock and has an option 
to purchase additional shares. As a result of these transactions, Roche became the 
biggest single shareholder of the company with 4.483.334 shares as of 31 December 
1999, according to the S-1 document filed by the company.  
deCODE’s success in attracting capital venture investment was also a crucial 
indicator of its ability to conduct such a comprehensive project. Through this 
agreement, deCODE strengthened its position in Iceland in the minds of politicians and 
indirectly the Icelandic people (Árnason & Wells, 2003). The symbolic presence of the 
Prime Minister of Iceland, David Oddsson, during the signing ceremony, the 
agreement, is also an indicator of the trust of politicians to deCODE’s future plans in 
Iceland (Sigurddson, 2001, p. 105).  Iceland has also started to become a global 
phenomenon through the power of the media. The reactions of the international media 





both sensational and also contained arguments of the support by the Icelandic 
authorities. For instance, an article published on BioWorld Today included the David 
Oddsson’s statements to support the foreign investment into the project: “It is extremely 
important for us to secure foreign investment in Icelandic companies, and I am 
delighted to see an investment of this size in a high-tech venture in our country” (Moran, 
1998).  The similar sentiments of Iceland's Prime Minister mentioning the agreement 
"as a huge step towards securing an important role in the Icelandic economy for high-
technology industries" hit the headlines in various biotechnology publishers (The 
Pharma Letter, 1998). provocative articles, even in journals with high reputations, 
made Iceland’s gene pool and deCODE Genetics known worldwide. One of the most 
striking examples of these attention-provoking articles is “Natural-Born Guinea Pigs” 
by Gibbs in the Scientific American in February 1998. The author defines the Icelandic 
population pejoratively as “270,000 citizens of this island nation, a great majority of 
them descended from seventh century Viking settlers, form one of the most inbred 
populations in the World”. The partnership with a global player in the pharmaceutical 
industry enhanced the appeal of the project and the Icelandic gene pool in addition to 
the strategic deals between the parties. 
The global attention increased deCODE’s financial capacity through further 
options such as public offering, providing the company with tools for speculative 
actions as well. According to Zoega and Andersen (2000, p. 37), after the signing of 
the contract, the value of the shares was around $5, and the total value of the deCODE 
was around $120 million. Before the launch of the deCODE’s shares publicly trade in 
NASDAQ in July 2000, on June 30, 1999, deCODE entered into a Stock Purchase 
Agreement to sell five million shares of the company to a Luxembourg-based financial 





of Icelandic banks and other financial entities for between $16 and $17 per share. The 
banks then sold about 40 percent of these shares to Icelandic investors (Greely, 2000, 
p. 169). The shares subjected to this sale belong to the venture capitalists who paid $1 
per share in 1997, although they are bought by Icelandic investors for approximately 
$16,50 per share, which sharply fell and never took off again (Arnason, 2007, p. 7). 
Furthermore, according to an article in Iceland Review (2005), the stock traded for up 
to $60 on the Icelandic gray market from 1998 – 2000; the article also questions the 
transactions to Luxembourg subsequently dissolved through Panama. As Fortun 
(2008, p. 259) indicates, six thousand Icelanders exposed the financial risk at the 
bottom of the speculative chain for the genomic slot-machine that they paid $65 to pull 
the handle in the case of this stock speculation. 
 Following the success of the Roche agreement, deCODE Genetics applied to 
the Icelandic government to demand the regulatory environment and the political 
support that they needed to launch operations for a comprehensive genome project. 
The first introduction of the bill in 1999 created considerable controversy and shed light 
on the aspect of relations among the company and politicians. However, Gardar 
Arnason (2007, 7) claims that deCODE, prior to explicit political debates, had been 
negotiating the bill with the Icelandic government, particularly with Prime Minister, 
Oddsson, and the Minister of Health, Pálmadóttir, since 1997 in a confidential manner. 
Moreover, Sigurddson (2001, 112) points out that the draft bill had been faxed by 
deCODE to the Ministry of Health and Social Insurance at the beginning of September 
1997.  His argument is based on a quotation from “Kári í jötunmóð” a book written in 
1999 by historian Gudni Thorlacius Jóhannesson, who has been the President of 
Iceland since August 2016. The Prime Minister’s endorsement on the agreement with 





shows the importance of foreign investments in the high technology-driven economic 
sector. In addition, the first female President of Iceland, Vigdís Finnbogadóttir, was 
recruited by deCODE as a board member to strengthen the nationalistic discourses 
embedded into the project.  
One of the vital points for political articulation is the support of the prominent 
public figures to the project. For instance, Finbogadottir, the first and only female 
President of the country, was recruited as a member of the board of the company. She 
had spoken frequently of the need for high-tech jobs to bring young Icelanders home 
during her presidency, in line with the center-right government of Oddsson’s 
enthusiasm for the new company. (Rose, 2001a, p. 16). deCODE’s promises of high 
technology investments into the country and contribution to the local economy 
accelerated the process of policy-making. As Vilhjálmur Árnason and Gardar Árnason 
(2004, p.173) state, proponents of the bill, in particular, the Prime Minister and the 
conservative MP Olrich, were in favor of a speedy process to conclude the debates 
about the formation of the HSD. The quick action was crucial because the market 
opportunities which made the database project feasible for a private company might 
suddenly evaporate in the volatile and fast-paced world of biotechnology and genetics. 
The ideological compliance between the deCODE targetting a market-based system 
for a health-related service and the center-right government that sees the foreign 
investments in the high-technology sector as a solution for the troubled economy 
following the turmoil in the fishing sector is a catalyzer for the HSD. 
  The Health Sector Database bill was first submitted to the Althingi, the national 
Assembly of Iceland, in March 1998. After the announcement of the draft bill publicly, 
a plethora of debates started both at the national level and the international level, and 





connect data from two other databases: a database with genealogical information that 
has been processed from public genealogical records and a database of genetic 
information that is processed from biological samples obtained for research by 
physicians cooperating with deCODE Genetics as well as the HSD based on the 
medical records itself (Árnason, 2010, p. 299). The Health Ministry was forced to 
withdraw the bill a month later, after fierce opposition from the Icelandic Medical 
Association and a unanimous appeal for postponement by the staff of the University of 
Iceland's Faculty of Medicine. The points that they criticize can be summarized as the 
storage of personal information without prior informed consent, the idea of the 
monopoly of a company over commodified medical records instead of being a 
collective property of a whole nation as Enserink (1998, 890) indicates.  
In addition to sessions in the Althingi, the proponents of the database legislation, 
mainly the representatives of the government and the deCODE, and opponents of it, 
mostly physicians and academicians, discussed their arguments in local and 
international journals. Representatives of the Icelandic Cancer Society, the Institute of 
Biology, the University of Iceland and the Icelandic Medical Association focused on the 
scientific, ethical and economic issues caused by the database model based on the 
monopoly of a private economy and perception of medical records as the commercial 
assets and demand the maintenance of the democratic traditions of the country rather 
than for-profit ends of a company (Eyfjörd et al., 1998, p. 496). Andersen (1998, p. 
1993), from the University of California School of Medicine, questions the "opt-out" 
clause added to the bill during the revisions, although there has been still no mention 
of the informed consent to be obtained from individuals whose data will be included in 





The proponents of the project highlighted the advantages of conducting such 
comprehensive research in Iceland as well as its contributions to the national economy. 
In this sense, a scientific project benefits from the setting in the country, providing a 
high quality of health care, detailed patient and genealogy records, and a well- 
educated public. According to Haraldsdodttir (1999, p. 498), then Deputy Permanent 
Secretary of the Ministry of Health and Social Security, despite ethical and legal 
concerns, the project gives Icelanders a unique opportunity to promote medical 
sciences because of its advantages to conduct population-based research and the 
dilemmas to preserve patient rights and the need for an informed public debate is 
recognized by the project.  
There are also some points regarding the origin of the opponents of the project. 
For instance, Pálsson and Hardardottir claim that (2002, p. 280) many of the 
spokespersons for the Association of Icelanders for Ethics in Science and Medicine 
seem to see their scientific dominion as being threatened or devalued by deCode 
Genetics and the Biogenetic Project. Ragnarsson (1999, p.1354) claims that during the 
debates, some claims are based on false information. For instance, the argument that 
legislation allows a private company to link its medical records with genealogical and 
genetic data is false because personally identifiable data cannot be linked to encrypted 
medical data in the central database. The legislation simply forbids such use, and it is 
made impossible through encryption.  
 The updated version of the bill was finally enacted in December 1998, which 
was not sufficient to end controversy caused by the project Act on a Health Sector 
Database is considered the first legal regulation in the context of biobanking 
(Schneider, 2012, p.184). According to this legislation, the objective is to authorize the 





data with the aim of increasing knowledge in order to improve health and health 
services. Within the context of the act, a health sector database will be established, 
which stands for a collection of data containing information on health and other related 
information, recorded in a standardized, systematic fashion on a single centralized 
database, intended for processing and as a source of information. The creation and 
operation of a health sector database are only permitted to those who have an 
operating license by the terms of this legislation. When an application has been 
received, the Minister of Health may grant an operating license to create and operate 
a health sector database subject to the further terms of this legislation. The licensee 
shall pay a fee for the grant of the license in order to meet the costs of preparing and 
issuing the license. The license will be for 12 years and will be renewable.  
The wholly-owned subsidiary of deCODE Genetics, Islensk erfethagreining ehf., 
received a license permitting them to develop and operate the IHD in January 2000. 
DeCODE is to pay the Iceland government 70,000,000 Iceland krona (approximately 
$950,000 US dollars) per year, as well as 6% of pre-taxable profits. Following the HSD 
Act, a new institutional environment was created for the database as well. The 
Monitoring Committee of the Health Sector Database, the Interdisciplinary Ethics 
Committee, the Data Protection Commission, and the National Bioethics Committee 
are crucial elements of this new system. The Data Protection Commission was 
restructured in 2001 with a broader mandate following new legislation on personal data 
and privacy. The National Bioethics Committee was established in 1999. The main 
change introduced by the regulation was that committee members were no longer 
nominated by academic and medical institutions but by various Ministries and the 





nominate members of the Bioethics Committee was moved from academic and 
medical institutions to the executive branch of government. 
The comprehensive database that deCODE planned includes medical records, 
genetic information, and genealogies, combining medical records with the other 
databases for scientific and commercial purposes (Pálsson, 2007, p. 96). In this 
setting, the healthcare data dating back to the early twentieth century will be collected 
through presumed consent, whereas participating physicians will take blood samples 
of the patients with informed consent. Additionally,  through a software of Frisk 
Software, a contractor of deCODE Genetics, genealogical data, including family 
histories of the Icelandic population dating back to the ninth centuries, will be 
constructed called the Book of Icelanders ( Pálsson & Hardardottir, 2002). Winickoff 
(2006, p. 82) claims that  HSD Act’s most controversial provision is the transfer of all 
medical record data to the licensee for commercial development without the express 
consent of individuals, by invoking a rule of the presumed consent. Stefansson and 
Gulcher further demand a mechanism which can be used for the cross-matching of 
medical information between the databases. Vigdis Stefansdottir, a Genetic Counsellor 
at Landspitali University Hospital who was interviewed in Iceland, sees a dynamic 
concept of informed consent as a solution to problems associated with the informed 
consent mechanism while conducting genetic studies:  
“Usually, when you are doing research with a large cohort when 
you may not able to say I am not quite sure this is the person, but 
you are making specific research on that person with her sample, 
I think dynamic consent is the way to go. If you have dynamic 
consent electronically, that is something online. When you are 
online each time, you have this cohort starting new research, and 
you inform participants online. You say this is the research and 
are you still willing to participate; this is the dynamic form of 
consent. I think this is the way to go. Many say it is complicated, 





Indeed, according to the act (Article Eighteen), Icelanders would have six 
months from the construction of the database to opt-out unconditionally, which is quite 
problematic in terms of ethics and the protection of individual rights. According to 
Arnardottir et al. (1999, p. 353), although the Act is consistent with the European 
Economic Area competition rules, which are binding for Iceland as a member, due to 
the uniqueness of the project, commissioning one party to create and operate a 
centralized health sector database, a certain risk is taken. For Gottweis (2012, p. 215), 
fundamental debate took place concerning the ownership of and access to genetic 
information and medical records, since deCODE, as a private multinational company, 
would have the power to explore the genetic bases in the entire Icelandic population 
and to then profit from this research. Because of these concerns, by June 2003, roughly 
20,000 people had opted out. However, the dimensions of the project which will 
combine the biological data and family histories of a whole nation, even if they will be 
all encrypted, to include ancestors who first settled in Iceland seem to more 
controversial, resembling the conditions of a dystopia. This is because a database that 
makes possible the total surveillance on genetic characteristics of a nation might cause 
eugenic policies to eliminate those who are susceptible to certain genetic conditions. 
 After the enactment of the HSD, the issue of democratically debating the draft 
bill was raised. The article written by the cofounders of deCODE Genetics, Gulcher, 
and Stefansson, relies on the quantitative aspect of the debate to prove its democratic 
feature on the ground that debate is one of the most important mechanisms by which 
complex ideas are processed by democratic societies. The controversy associated with 
the bill included 700 newspaper articles, more than 100 radio and television programs, 
and several town meetings all across Iceland, which according to the authors, provide 





p.1827). They also submitted the results of the polls that they organized themselves. 
For instance, on the eve of the parliamentary vote, a poll showed that 75 percent of 
Icelanders supported the passage of the bill, whereas 25 percent were against it. The 
database law was passed by the same margin, and since then, support for it has been 
growing. A poll taken by the Gallup organization at the beginning of April 2000 showed 
that 90 percent of those who took a stand on the issue supported the data-base law, 
and 10 percent were against it. In that way, the national media coverage functioned to 
propagandize the arguments of the project, therefore diffusing the discourses into the 
Icelandic society. 
The arguments about broad media coverage that gives debate a democratic 
aspect have been affirmed by some articles, such as, Pálsson and Rabinow (1999) 
and Pálsson and Hardardóttir (2002). However, a media analysis of the debates about 
the Icelandic genome project conducted by Hjörleifsson et al. (2008) shows different 
perspectives than those of the proponents of the database. According to the study, 
positive media presentation of deCODE’s research, initiation of new studies and 
cooperation with international industry or Icelandic and international institutions, 
enthusiasm and optimism about success for the company surpass the views stated by 
its critiques as the points of views of the opponents were not pursued by journalists 
and were in effect overshadowed (Hjörleifsson et al., pp. 383-385). deCODE’s 
registration on the NASDAQ stock exchange in the US harmed Icelandic investors due 
to market speculation. However, the media coverage on Ríkisútvarpið (RÚV) on 18 
July 2000, the Icelandic National Broadcasting Service, was in a different tone, 
exemplifying the national pride on the project.  
This is a very big day for the Icelandic financial sector and I would 
say for the entire national economy. . . . We are talking about 





correct our foreign trade balance. . . . We are now exporting 
services. . . intellectual capacity and . . . Icelandic knowledge, 
Icelandic information, Icelandic genes. (Hjörleifsson et al., p. 386) 
 
The focus groups based research conducted by Traulsen et al. ( 2008), confirms the 
national solidarity of Icelanders on genomic research in the country and positive 
attitudes towards deCODE among laypeople instead of privacy concerns. As such, the 
economic expectations of Icelandic people and national values were articulated 
successfully with the achievements of the project in media coverage.  
Individuals were encouraged to be active subjects of discourse of health, around 
genomic research and precision medicine, in Iceland through their participation into the 
Icelandic genome project. On the one hand, participation in research provides 
researchers with health data that they need to construct pedigrees of diseases and 
statistical correlations between the clinical data. This was affirmed as complying with 
the moral obligation. On the other hand, the active involvement to research subjects is 
affirmed as a norm or moral obligation by governing individual conducts. The research 
participation as a moral obligation is justified by some authors, for instance, Rhodes 
(2005, 15): 
“Since World War II, we have witnessed a dramatic increase in 
biomedical knowledge and tremendous progress in creating 
effective treatments for disease. These are benefits that flow from 
human subject research. We are also aware that we stand on the 
brink of a cascade of insights into human genetics and the 
promise of spectacular related advances in biomedical 
technology. Furthermore, we would want medicine to be able to 
provide effective treatment when we or our loved ones should 
need it. Without human subject research, those treatments are 
less likely to be available. So, in light of our appreciation of human 
vulnerability to injury and disease and our appreciation of the 
value of clinical research, reasonable people should endorse 
policies that make research participation a social duty.” 
In this sense, biobank projects, including the Icelandic Genome Project, functions as 





active subjects of health discourse. This function is in parallel with self-rational patients 
who are expected to pursue their personal enhancements as the consumers of new 
health technologies. 
Specific political settings result in the specific articulation of the local priorities 
to the settings of global economic projects such as genomic databases. Prainsack 
(2006, p. 232) points out, to understand a discursive creation of a particular risk setting, 
a particular understanding of risk with regard to genomics, and the microphysics of 
power inherent in them, we need to turn our attention towards politics. As Gottweis and 
Petersen (2008, p. 8) posit, in Iceland, like Israel, narratives of genes as national assets 
co-exist with privatizing tendencies in biobank development. In this sense, the global 
conjecture, the crisis in the local economy, and the ability of the project to articulate the 
national discourses were the factors that enabled the project to survive in spite of 
financial turbulence through stock share value of the company.  
In the theoretical debates, there are analyses supporting the project in spite of 
contentious points regarding its ethics aspect, which dominated the discussions in 
parallel with the notion of individual autonomy. The opinions endorsing the project, in 
general, focus on the economic impacts of the project within the global conjecture. The 
controversial practices of the project are justified by the arguments on the ground that 
private and public hybrid model succeeds at the mobilizing sources effectively. For 
instance, Rabinow and Pálsson (2001, p. 171) claim that “without private initiatives, the 
potentially powerful resource represented by the synergies of combining medical, 
genetic and genealogical information would have been left unused. Although biopiracy 
is a very real threat in the modern world, fear of corporate power should not blind one 
to the possibilities of reconciling individualistic and collective enterprises” In this 





concerns associated with human genetics research. Therefore, the countries with 
resources that are of economic value in terms of genomics are supposed to use them 
rather than waste it. Pálsson and Hardardóttir point out the increasing research 
capacity in the country and foreign investments as a result of the project. In this sense, 
the project created many new positions for scientists both within the company and at 
the University of Iceland. The company attracted much investment from abroad and 
created numerous jobs for Icelandic scientists, many of whom, in the absence of 
deCODE Genetics, would have been forced to seek employment abroad (Pálsson & 
Hardardóttir, 2002, p. 280).  
Following the debates on the concerns about the Icelandic Health Sector 
Database, which was a product of a special law to construct a database, the project 
came to a halt because of a juridical action. The Icelandic Supreme Court ruled in favor 
of the plaintiff Ragnhildur Gudmundsdóttir who demanded her father´s name be put on 
the abstainers list held by the Directorate of Health in 2003. In this case, the Supreme 
Court decided that the Act on the HSD does not meet the requirements in the Icelandic 
constitution to provide adequate protection against the risk of the data being traced 
back to the relevant individuals for the purpose of protecting their privacy. In this way, 
the concerns about the privacy and the protection of personal data in the HSD, which 
was campaigned against by medical experts, was acknowledged by a juridical 
authority. 
 HSD was never set up but deCODE continued its research in Iceland regarding 
the genetics of common diseases. The company even started clinical trials on drugs 
after the decision of the Supreme Court.  Although deCODE did reach many of the 
milestones of the agreement with Roche in 1998, it continued to co-operate with Roche 





data of the Icelandic population without a centralized database of health information 
(Árnason, 2007, p. 9). In the aftermath of the collapse of the database project, there 
has been neither specific research of deCODE on multiple sclerosis nor therapies 
developed through gene studies on the Icelandic people, although Stefansson’s work 
with MS patients was used as a propaganda topic while attempting to mobilize public 
support for the public support for the project. Moreover, there has been no free 
medication given to Icelandic people, as promised during the Roche agreement.  
The Supreme Court decision affected the stock performance of deCODE 
Genetics, which was floating around $2 and $3 per share, therefore worsened the 
financial capacity of the company. Following the global crisis in 2008, deCODE was 
not able to proceed with its operations further, first quitted the NASDAQ index, and 
then filed for bankruptcy. Holding the valuable genetic information of the Icelandic 
population, deCODE Genetics managed to find a new partner in 2012 and has been 
acquired by the US biotechnology giant Amgen, with a purchase value of $ 415 million. 
The company continues its operations as a fully-owned subsidiary of this company as 
the date of this thesis. 
In the collapse of the project, the attitude of medical experts is crucial. Pálsson 
(2008, p.  42) claims that one of the main reason for the fall of the project is what he 
calls as biopolitics of the dispossessed which means the strategies of the resistance 
of the segments of the Icelandic medical establishment who feared the loss of their 
control and the security over medical practices in the country. The opponents of the 
HSD, who are mainly the physicians and academicians, organized under an 
association called Mannvernd (the Association of Icelanders for Ethics in Science and 
Medicine) in October 1999. It is not fair to describe these experts as reactionary forces 





medicine, because their dominance in knowledge production was challenged. In a 
nation where NGOs are far from common, the emergence of Mannvernd was, in many 
ways, as significant a social and political event in Iceland as deCODE was, because 
this organization not only led the organized opposition to the HSD legislation but also 
initiated an education campaign to raise the level of public discussion about genomics 
and the project (Fortun, 2008, p. 19). This alternative way of knowledge production is 
probably one of the most prominent aspects of the Icelandic genome project. The large-
scale genetic research projects and database attempts resulted in the unification and 
a monopoly in the knowledge production in parallel with existing discourses. In the 
name of the raising health literacy on genetics, these efforts are also being encouraged 
by international organizations campaigning for the application of genetic knowledge in 
public health as well.  
3.3) Conclusion 
In the Icelandic genome project, beyond the contradictory points regarding the 
consent mechanism and how the project was conducted, the commercial ends 
surpassed the public benefits. The collaboration of the Icelandic government with 
private enterprise set the conditions for a monopoly through a comprehensive 
regulation, which in turn exploited the public health data for-profit initiatives instead of 
supporting public health outcomes. The specific political-economic conditions in 
Iceland necessitating foreign investment after the collapse of the fishing industry and 
the competition state that was willing to invest in knowledge economies were the crucial 
factors for this comprehensive project. As a result, the establishment of a database to 
detect the genetic causes of complicated disorders for the benefit of public health in 
the name of a revolution in medicine and contribution to the local economy became 





 It is possible to observe the limited effect of the project on health care practices 
in the country. According to an interview with an Icelandic scholar (Interviewee 2), the 
unique aspect of genomic studies in Iceland was the cascade screening of the 
investigation of family members of the cancer patients performed electronically through 
computer technologies. Except that, the comprehensive scope of the genetic studies 
in the country has been conducted with traditional understanding in parallel with the 
practices in the other Western countries. The views of the interviewee on the conduct 
of the Icelandic genome project that  
“There are two major faults associated with the database. One 
fault is that there was no return on research regardless of how 
much information was relevant to participants. There was no 
mechanism to get out the information to the patients. The second 
one is the way the database was supposed to work. It was going 
to be protected by a monopoly. If there were no monopoly, then 
it would be considered to illegal to do things in this way. That is 
not how you apply monopoly. Let say the monopoly of 
transporting patients, or a transport company, transporting goods 
and services between City A and City B. That is a monopoly in 
which nobody else commercially transports. A monopoly never 
allows the monopoly to do things illegally if you do not have a 
monopoly. As a transport company, there will be no monopoly for 
driving faster than anyone else, driving faster than the speed limit, 
not stopping at red lights, etc. Part of the database is set up on 
that if we did not have a monopoly and someone else wants to 
similar things, there would be illegal.” (Interviewee 2, Icelandic 
scholar, 2019). 
deCODE succeeded in not only funding of the project through speculative stock-
market transactions but also convincing Icelanders to support the project; in other 
words, not to opt-out from the database. The hybrid mechanism successfully 
articulated the nationalistic discourse with the project according to which it would 
contribute to the protection of the unique Icelandic genetic heritage. Even though the 
project collapsed and deCODE bankrupted during the financial crisis, the company 
managed to survive merging with a US biotechnology company because of the 





information for commercial ends, a threat of the biopolitical control of individuals who 
consented to transfer their biological information to a comprehensive database for the 






CHAPTER FOUR-NEWFOUNDLAND AND LABRADOR 
4.1) Overview 
This chapter examines genetic research in Newfoundland and Labrador, and 
the province’s governance mechanisms in relation to public health practices. The focus 
of this section is the provincial approval model proposed as a governance alternative 
in the province. This model is developed by the province’s academic community and 
embraced by governmental institutions on the basis of the benefit-sharing principle. In 
this chapter, the private sector endeavors in genomics in the province, particularly 
Newfound Genomics, are also discussed. In order to analyze the emergence of 
investments into the genomics, this chapter will also explore the research context in 
Newfoundland and Labrador. The Baylor College of Medicine’s 1998 research project 
in Grand Falls, NL, occupies a central position because it affected the province’s 
subsequent research activities and policies. Specifically, the project was called Texas 
Vampires by local people, and it strengthened the rhetoric of the requirement for the 
involvement of local scientists in research projects. Finally, this chapter will also 
examine the NL Genome Project, an ongoing local research study led by the 
biotechnology company Sequence Bio, which represents the second wave of the 
private enterprises into the Newfoundland genome pool. 
Newfoundland and Labrador has a long history of publicly funded genetic 
research driven by scientists based in the province. These activities date back to at 
least the 1980s (Rahman et al., 2003), while Pullman & Latus (2003) point out thirty 
years of research history in the province. Prior to increasing focus on genomic studies 
together with the HGP, scientists from the Memorial University of Newfoundland were 
the leading players of the research into genetic roots of diseases with high prevalence 





scientific community both at the national and international levels because genomic 
studies in the province were limited. For example, researchers at Memorial University 
worked with John Hopkins University to detect a gene responsible for specific colon 
cancers and with McGill University to work on a gene linked with a form of hereditary 
ataxia. These events exemplify partnerships with outsider researchers. These projects 
exemplified well-functioning cases of scientific alliances to conduct research on local 
communities in the Policy Implications of Commercial Human Genetic Research in 
Newfoundland and Labrador Report (2003, pp. 10-11). The involvement of local 
researchers was a decisive factor that gave legitimacy to the research projects and 
proclaimed as a prerequisite by academia and provincial government, for both the 
scientific success of the projects and the protection of communities targeted by that 
research.  
The scientific motive behind the interest in the province, like in Iceland, relies 
primarily on the argument that genetically homogenous populations serve for ideal sets 
to conduct genetic research to detect the roots of the diseases because of the high 
prevalence of genetic disorders. These disorders are often linked with the existence of 
the founder effect, which is the establishment of a new population by a few original 
founders resulting in minimal genetic variation ( Diamond & Rotter, 1987, p. 105). The 
population of Newfoundland that descended primarily from European immigration from 
Southeastern Ireland and Southwestern England is prone to certain monogenic 
diseases because of the founder effect and inbreeding factor (Zhai et al., 2016, p. 
1068). The incidence of the Bardet-Biedl Syndrome (BBS), a rare genetic disorder in 
the province, is ten times that of white people of northern European ancestry because 
of the founder effect and subsequent isolation (Young et al., 1999, p. 1680). The 





medical units to study these conditions in the province. According to the Newfoundland 
and Labrador Medical Association, the province itself established a Medical Genetics 
Program in 1986 because of certain genetic disorders  
4.2) The Emergence of research activities in the province 
The first private-sector enterprise for genomic research in the province is the 
Newfound Genomics. This company was established in 2000 as a joint venture of 
British biotechnology company Gemini and a small NL company, Lineage Biomedical. 
The year in which the company was established marked a rush for genome sequencing 
following the Human Genome Project (HGP). In this sense, this joint-venture company 
with a local partner reflects the endeavors in search of new sites for research following 
the path of the HGP.    
In the period following the launch of the HGP, there is also an increase in the 
scientific publications about the populations promising advantageous settings for 
genetic research, including Newfoundland. For instance, in a collaborative article led 
by the researchers at the Memorial University, the population of the province was 
described as one that had explicit advantages for genetic studies as compared to less 
homogenous populations, as well as to similarly isolated populations (Rahman et al., 
2003). During that period, it is also possible to observe the revival in scientific studies 
with similar themes, such as (Zhai et al., 2016), during the second wave of private 
enterprises represented by Sequence Bio into the Newfoundland gene pool. 
The province attracted the interest of national and international media in the 
onset of genomic age, which was triggered by the HGP, and private enterprise to 
sequence genome in the province. The media coverage of genetic research was a 
crucial point to both encourage investment into the sector and also to increase the 





2000 is an example of interest in genetics. This article makes an explicit comparison 
of the Icelandic Genome and overseas investments of British company Gemini into 
Newfoundland’s gene pool through Newfound Genomics. Being aware of the 
controversial aspects of the project in Iceland regarding patient confidentiality and 
ownership of human genes, Meek (2000) emphasizes the difference between 
Newfound Genomics and its Icelandic counterpart. In this article, Gemini's clinical 
director and vice president, Howard Christley’s statement, describing the population of 
the province as the “inbred population“ was also underlined. Atkinson’s article in the 
Globe and Mail in the same year also includes a comparison between Iceland and 
Newfoundland. The author depicts the gene pool of the Newfoundland as a priceless 
commodity and predicts that the province can benefit from its genetic legacy (Atkinson, 
2000). In the article, the arguments of Dr. William Davidson8 are cited, who is in favor 
of an alliance with a cash-rich pharmaceutical giant in parallel with Iceland. 
The salience of the genetic pool of the province and investments into this source 
got media coverage with slightly different tones.  For instance, in a more critical account 
of the developments in the province, Staples (2000) in the Globe and Mail discusses 
the inadequacy of framework concerning the use of medical data in research activities. 
Taubes (2001) in MIT Technology Review, examines the strategies of Newfound 
Genomics as a venture investment in which the target was summarized as to develop 
an international hub of clinical genetics for the benefit of the province and the patients 
around the world suffering from the diseases that company tried to detect its genetic 
roots. In the media coverage of the Newfoundland case, the comparison with Iceland 
is the most characteristic feature of the publications by attempting to make the province 
 
8  Davidson was the Dean of Science at Simon Fraser University at the time. Before this 






more known in the international area and illustrate it as a new model and site which 
has similar characteristics with Iceland in terms of genetic legacy but differs from its 
contradictory way of processing genetic data.    
Among the increasing attention to the province, Newfound Genomics was 
established as a joint venture of Gemini Genomics plc, a biotechnology company 
based in Cambridge, the UK, and Lineage Biomedicals Inc., based in St. John’s 
Newfoundland and established by local physicians. According to the United States 
Securities and Exchange Commission (SEC) data filed in 2000 as a NASDAQ listed-
corporation, Gemini Genomics, operates in the fields of clinical genomics to identify 
the relationships between human genes and human health and disease since its 
establishment in 1995. The founder and chairman of the company was Michael 
Fitzgerald, who was a barrister specialized in the provision of international banking and 
corporate legal services. Lineage Biomedicals, the local partner of the joint venture, is 
led by Dr. Wayne Gulliver, who works as a dermatologist in St. John’s. As a 
Newfoundlander, Dr. Gulliver, who studied medicine at Memorial University, worked 
on psoriasis, which has a high prevalence in the province.  
Gulliver had experience of collaborating with outside researchers before the 
Newfound Genomics. He participated in previous genetic research conducted by a 
California based biotechnology company Celltech about this disease by collecting 
samples in the province (Pullman & Latus, 2003, p. 549). Taubes (2001) states that 
Gulliver met Paul Kelly, CEO of Gemini Genomics, which had already assembled a 
huge international network of twins to use in searching for gene-disease associations, 
and convinced him to extend the company’s network to include the unique gene pool 
of the province. It looks like this joint venture was also in parallel with the strategy of 





increased its collection of clinical samples and its ability to access further clinical data 
through its acquisition of Eurona in December 1999. Based in Sweden, Eurona 
provided Gemini Genomics with access to several million tissue samples and genetic 
materials from volunteers affected by a range of diseases because of clinical 
collaborations with university and medical institutions that they had made before the 
acquisition. In this sense, the partnership with a local company which was also led by 
reputable physicians in the province was an appropriate strategy both to satisfy the 
expectation for the involvement of local people and also to enrich the clinical data 
considering the fact that Gemini Genomics was founded and chaired by an 
entrepreneur investing in the promising sectors. 
The company then started its preparations to conduct genome research for 
specific diseases in the province by recruiting local scientists and projecting its 
facilities. In this context, Dr. Proton Rahman, professor at Memorial University, was 
appointed as a chief scientific officer to manage sample collection processes. Another 
significant person in the province Siobhan Coady, a successful entrepreneur and 
current Minister of Natural Resources of the province was named as the CEO of the 
company who held this position until she entered the politics in 2008.  With regard to 
investments into facilities, Newfound Genomics purchased a freehold property in St. 
John's, Newfoundland. This property was designed to be used to provide facilities for 
sample collection, office space, and laboratory facilities for the company's operations 
(United States Securities and Exchange Commission Form Annual and transition 
report of foreign private issuers, 2001, May 23). In February 2001, Gemini Genomics 
acquired the outstanding share capital it did not then own from Lineage Biomedical 
Can for $60,000. This amount was recorded as goodwill since the joint-venture had no 





commitments to the benefit-sharing model and contributions to the funding of research 
facilities at Memorial University, such as the purchase of gene sequencer for the 
university, as stated in the news release of Industry, Trade, and Rural Development in 
2001. However, another development in 2001 seems to affect negatively the funding 
possibilities of the company, which is the acquisition of Gemini Genomics by 
Sequenom of San Diego, California. After this merger, Newfound Genomics had to 
continue its operations, a single company depending primarily on government support. 
Although the company managed to get support from governmental agencies and 
academia, without adequate funding or opportunities for speculative stock-market 
transactions, like in Iceland, it is highly unlikely to accomplish the genomic research. 
During the recommendation for the provincial approval model and the formation 
of legislative framework associated with it, Newfound Genomics was in a close 
relationship with Memorial University and the provincial government.  As an example 
of academic collaborations, the company, while doing research for developing a 
pharmacogenetic diagnostic test to predict drug response in patients partnered with 
the Population Therapeutics Research Group (PTRG), a non-profit research team led 
by Dr. Rahman in the Faculty of Medicine at Memorial University in 2006. The company 
collaborated with the Genesis Group, the technology commercialization arm of 
Memorial University, to pursue a program of collaborative research and to bring the 
potential pipeline of promising discoveries to the market in 2008. In this context, the 
company committed to developing a diagnostic genetic test for arrhythmogenic right 
ventricular cardiomyopathy, a deadly genetic heart condition highly prevalent in the 
province called as “Newfoundland curse” killing young people without any prior 
symptoms, whereas researchers at Memorial University worked on the discovery of 





represented the province in reputable technology conferences, such as BIO 2002 in 
Toronto, an international biotechnology convention and trade exhibition. Whereas the 
delegation for the event was organized by Bio-East, the Newfoundland and Labrador 
Bio-Technology Network, and The Department of Industry, George Sweeney, 
Parliamentary Secretary to the Minister of Industry, Trade, and Rural Development for 
Information and Advanced Technologies and Dwayne Goudie, Managing Director of 
Bio-East made statements about the strategic growth opportunities in biotechnology 
as knowledge-based industries and government’s commitment for expanding the 
biotechnology base (Government of Newfoundland and Labrador, Industry, Trade and 
Rural Development, News Releases, June 07, 2002). The company also took part in 
the Boston Trade Mission as a member of  Team Canada Atlantic, which is a 
partnership of ACOA, Agriculture and Agri-Food Canada, Industry Canada, Foreign 
Affairs and International Trade Canada, Enterprise Cape Breton Corporation and the 
four Atlantic Provinces. The provincial government supported the company as an 
enterprise in the high-technology sector, increasing the competitiveness of the 
province in the knowledge economies model just as the provincial approval model as 
a legislative framework did.  
The provincial government supported who wanted to benefit from the influx of 
capital investment into local economy Newfound Genomics in different ways. The 
company was also awarded the St. John’s Board of Trade Business Achievement 
Award, a reputable accomplishment granted in the mandate of Innovation, Trade, and 
Rural Development (The Department of Innovation, Trade and Rural Development, 
Annual Report, 2007). The company got direct financial funding from the provincial 
government during the economic crisis period. NewLab Clinical Research, a group 





and Rural Development within the commercialization program, whereas Newfound 
Genomics got another $ 500.000 in 2008 from the same program (Office of the Auditor 
General Newfoundland and Labrador, 26 January 2011). However, these financial 
supports were unable to save the company, which, following the financial crisis ceased 
its operations in 2011. Additionally, the same year an investigation by the Auditor 
General regarding the funding to two group companies detected several issues on 
these transactions, such as, the owner of two medical research entities did not 
contribute any of the required $855,000 equity contributions, the Department did not 
complete proper due diligence relating to the approval and assessment process, 
disbursement of funding and monitoring, e.g., contrary to Treasury Board policy, cross-
departmental checking for amounts owing to Government was not fully completed; 
documentation was not adequate to support any of the $5.2 million in estimated project 
costs. 
4.3) Provincial approval model and the regulation of research in the province 
Increasing interest in genomics both as a burgeoning field of science promising 
a revolution in medicine and also as a high-technology to invest in for quick returns 
makes the province attractive for gene hunters. The activities of outside researchers 
as a result of increasing interest in genomic studies, mainly the infamous works of 
Baylor University in the province, who did not coordinate with local counterparts, have 
led to concerns (Pullman, 2005). These challenges from outside call attention to the 
necessity for the governance of genomic research, or at least appropriate legislative 
action, instead of seeing the involvement of local researchers into genetic studies as a 
balance factor. The challenges were not merely caused by the commercially driven 
genetic research in the province. As was the case in the works of the University of 





disease associated with HLD cholesterol whereas local scientists were unaware of the 
project until a newspaper headline criticizing the dietary habits of the Newfoundlanders 
(Pullman & Latus, 2003, pp. 547-548). The fact that the direct intervention of outsiders 
was regarded as a threat constitutes the foundation of the model proposed by local 
scientists and adopted by the provincial government thereafter as there was no 
regulation to regulate research on human genetics in the province. 
In the efforts to develop governance mechanisms, the provincial government 
called on expert knowledge. Dr. Verna Skanes, retired Assistant Dean of Research 
and Graduate Studies at the Faculty of Medicine at Memorial University and a member 
of the Standing Committee on Ethics of the Medical Research Council of Canada, was 
selected to prepare a report about issues associated with human genetic research 
(Government of Newfoundland and Labrador, News Releases, May 2, 2000). The 
commercialization of human genetic research, which was conducted by outside 
researchers investigating the DNA of Newfoundland families without informing them 
about the research results on the contrary to ethical guidelines applicable, was pointed 
out as the factor to ask for expert knowledge. In the report, issues such as research 
ethics, legal protection for the research participants, informed consent, and privacy and 
confidentiality, as well as the establishment of a provincial research ethics board were 
discussed. Additionally, the Ministry of Health and Community Services, as per this 
news release issued the Honourable by Roger Grimes, projected to set policy and 
standards for genetic research reviewing the genetic research policies around Canada 
and the world, particularly mentioning Iceland as a case. As can be seen in this new 
release, the issues addressed in the report bear the perspective of governance mode 
based on the provincial ethics board in that the level of genetic research targeting the 





Initially, the governmental agencies focused on the commercialization of genetic 
research to be addressed in a report by an expert in the field ( Pullman, 2005). In this 
sense, academic research, which is to be conducted by outside researchers and 
limited with public health ends, will be excluded. According to Botting (2001, pp. 73-
74), public health authorities had concerns about the activities of recently-established 
Newfound Genomics, and Dr.Skanes points out that the ethical and legal framework 
composed of Tri-Council Policy Statement for Research Involving Human Subjects are 
not sufficient to regulate the genetic research that has facilities to investigate the 
complex genetic disorders because of the biotechnological developments in parallel 
with the HGP. However, the recommendation for an ethical board in the report seems 
to represent a change of the perspective from a limited concept of the alleviation of the 
side impacts of commercialization to an authority granting the legitimacy to the 
research proposed. For Pullman (2005, p. 76), Skanes broadened the content of the 
report; as a result of her consultations during the preparation period, thus emphasizing 
the need for the “legislative oversight “of all health research regardless of the purpose. 
The framework for a provincial ethics board projected in the following policy 
recommendations is grounded on this ethico-legal concept of the legitimacy of genetic 
research. 
A novel concept of a benefit-sharing model, which was declared by the ethics 
committee of Human Genome Organization, a prominent international non-profit 
organization regarding genomic studies, is of significant impact on the genomic 
governance model in the province. The promotion of the model in 2000 coincides with 
the developments in the same year in the province affecting the future path of genomics 
locally, the establishment of Newfound Genomics in February 2000, and the Skanes 





share of private sector investments on genetic research according to the organization. 
The HUGO Ethics Committee Statement (2000a, p. 366) recommends that “in the case 
of profit-making, the general distribution of benefits should be the donation of a 
percentage of the net profits (after taxes) to the health care infrastructure or for 
vaccines, tests, drugs, and treatments, or, to local, national and international 
humanitarian efforts.” The emergence of the private sector genetic research in 
Newfoundland and policy recommendations of the local academic community with 
regard to the governance of these activities comply with the statement of the 
committee. Another publication (2000b, p. 49) of the Committee particularly endorses 
Newfound Genomics, which devotes 1% of net profits to a charitable trust for the 
general population. In addition to this, the emphasis on communitarian rhetoric to 
“ascertain community value and needs” and “ build greater trust and reciprocity with 
participants” as outlined by Knoppers (2000, p. 214), then chair of HUGO Ethics 
Committee,  increased the popularity of benefit-sharing among academia in the 
province, which is frequently compared with Iceland. In this sense, communitarian 
influence on ethical debates is not only limited with the community values but also 
includes “collective intellectual property and the socially embedded nature of the 
human individual will”(Pálsson & Rabinow, 167,2001). In benefit-sharing model, the 
influence of communitarian perspective goes beyond the affiliation with the community 
values and property rights on human genes, extending into assuring distributive justice 
of benefits created through genetic research.  
On the policy side, the ethics board and related regulations continue to be 
discussed following recommendations for the legislative action. In 2003, a project 
team, the members of which were affiliated with  Memorial University except for a 





Commercial Human Genetic Research in Newfoundland and Labrador Report for the 
Newfoundland and Labrador Department of Health and Community Services. This 
report authored by Associate Professor of Medical Ethics Darryl Pullman and a post-
doctoral research fellow Andrew Latus, recommend the establishment of a Provincial 
Approval Model which requires the benefit-sharing proposals as well as ethics approval 
to conduct genetic research in the province. While locating benefit-sharing centrally in 
the model, the report also recommends the creation of a Health Research Ethics Board 
(PHREB) and a Standing Committee on Human Genetic Research (SCHGR). 
According to the report, the genetic research proposal in Newfoundland and Labrador 
should obtain the approval not only from the PHREB but also from the SCHGR by 
submitting a proposal for benefit-sharing to the latter one. In this model, a committee 
composed of experts appointed by Minister of Health and Community Services, the 
President of Memorial University, and the Minister of Industry, Trade, and Rural 
Development will decide on the potential benefits of the research into communities in 
the province, ensuring the legitimacy of the proposals. According to the report, the 
implementation of the model will make the province a leader regarding the regulation 
of human genetic research, increasing the competitiveness of the province in parallel 
with the strategies on the investments into knowledge economies. 
In the Policy Implications of Commercial Human Genetic Research in 
Newfoundland and Labrador Report (2003, pp. 4-6), the ethical challenges were 
regarding research on human genetic were addressed to present a model which would 
comply with the ethical principles, as well as legal and social norms. These challenges 
consist of the legal status of human DNA, the ownership of it, privacy and protection 
concerns associated with genetic information, human dignity and new intervention 





results with research subjects are ethical standards to address the challenges, the 
violation of which breaches serious cases of victimization. Research activities, like 
Texas Vampires case, in which health research ethics on the consent mechanism and 
the disclosure of research results were violated, bear the risk of victimization of 
research participants in the expectation of the remedy for the disease. In this sense, 
the report prepared by Pullman and Latus addresses the ethical challenges that stem 
from universal principles regarding research ethics and the precautions to regulate 
health research in the province to protect local people form the risk of victimization.     
The particular cases in the history of genetic research illustrate how the breach 
of ethical principles, most notably, the informed consent mechanism and the disclosure 
of research results with participants result in the victimization. As was the case in the 
story of Henrietta Lacks, an African America woman, whom tissue samples passed to 
researchers without her consent during the medical procedures were at the Johns 
Hopkins Hospital for cervical cancer in the 1950s and grown outside body by 
researchers after her death (Beskow, 2016). Whereas the HeLa cell in vitro cultivated 
from Lacks’ tissue samples were not patented, in the case of John Moore, the cells 
collected from the leukemia patient Moore’s spleen at the University of California, Los 
Angeles (UCLA) were used to develop a cancer drug. The discovery was patented by 
the Regents of the University, naming it Mo cell, although Moore had consented and 
received no economic benefits. Moore’s lawsuit to benefit from the patent was denied 
by the Supreme Court, but it sparked debates on the role of property rights and the 
human body and parts. According to Wald (2005, 221), Moore’s case also sheds light 
on the biocolonialism in that an unempowered white man turned into a position which 
was open for the exploitation just as indigenous people suffered from DNA research 





gendered impacts of genomic research and the requirements of the ethical standards 
to regulate these research activities as outlined in the Policy Implications of 
Commercial Human Genetic Research (2003). 
The provincial approval model developed by the Newfoundland project team, 
mainly by Pullman and Latus, influenced not only the legislative framework concerning 
the provincial ethics board but also was discussed at the international level as a policy 
and governance alternative for genomics. The Scottish scholars Gill Haddow, Graeme 
Laurie, Sarah Cunningham-Burley, and Kathryn Hunter affiliated with the University of 
Edinburg elaborated on the Newfoundland model in their collaborative work. According 
to the authors (2007, p.279), the provincial approval model based on a benefit-sharing 
proposal reviewed by the provincial board deserves to be endorsed in that this model 
takes three principles into consideration, which are distributive justice, respecting the 
communal nature of the information contained in DNA, and public administration and 
promotion of health as a common public good. The community-focused approach 
about the beneficiaries of the benefits, comprehensive account of benefit to include 
community’s interest in health and wealth benefits in the model, convinces the authors 
to accept benefit-sharing as responsibility of both researchers and private enterprises 
as part of the entire governance framework (Haddow et al., 2007, p. 280).  
The Newfoundland model and its endorsement during the Generation Scotland, 
the Scottish biobank debate received several responses. This database projects to 
construct a database with family histories of the common diseases in Scotland. During 
the concerns about the commercialization of genetic research  Haddow et al. (2007) 
proposed a model of benefit-sharing. Reardon (2017, p. 106) criticizes this model 
developed, in parallel with the benefit-sharing model the authors endorsed in that it 





to be more inclusive regarding the definition of benefit. Elger (2016, pp. 248-49) 
questions the possibility of an international committee specialized in benefit-sharing 
instead of what is modeled in Newfoundland as a provincial one to serve for national 
ethics committees. The author also questions the potential side effect of benefit sharing 
on the condition that model would create an incentive for economically disadvantaged 
persons encouraged to participate in research. Winickoff claims (2008, p. 9) that in the 
Newfoundland model individuals or collective groups are not able to control the choices 
about biovalue creation, in that the model gives the authority for the allocation of 
collective goods through biobanks to the expert decision-makers, to avoid of potentially 
conflicting goals, e.g., between building local economic value and advancing global 
research access. These academic discussions about the reception of the provincial 
approval model highlight the different aspects of the model, such as regulatory basis 
and its impact on economic development. In addition, the benefit-sharing model, in 
general, accepts the distribution of benefits as a basis. In this sense, the model shifts 
the emphasis from dialogue to exchange or distribution” (Hayden, 2007, p. 732). In the 
last instance, the concept of legitimacy in a juridical sense, aiming to end of distributive 
justice based on the decisions of experts, which is capable of making a judgment on 
the benefits for the community according to the community values, represents a strict 
biopolitical regime ignoring the individual demands and intrasubject relations. 
The recommended legislative framework, in association with the provincial 
approval model, was implemented in the province in 2011. The Personal Health 
Information Act (PHIA) came into force on April 1st, 2011, the Health Research Ethics 
Authority Act, and the Health Research Ethics Authority (HREA) of Newfoundland & 
Labrador came into effect on July 1, 2011, serve for the intended framework during a 





disclosure of personal health information to protect the confidentiality of that 
information and the privacy of individuals, mechanisms that govern individual access 
to personal health information, and responsibilities of the persons/institutions who act 
as custodians of personal health information. Whereas PHIA includes provisions 
regarding the privacy of personal health information and mechanisms and 
responsibilities for custodians to protect individuals from the disclosure of their 
confidential information, the research that obtains approval from a research ethics 
board under the Health Research Ethics Authority Act is exempted from the obligations 
on the disclosure of the personal health information. According to the article (2012, p. 
40), authored by Patricia Kosseim from the Office of the Privacy Commissioner of 
Canada and academicians from the Faculty of Medicine and Population Therapeutics 
Research Group at Memorial University, including Daryl Pullman, “the unique 
legislation creates a province-wide research ethics authority to ensure that all human 
health research is reviewed within the province and conducted ethically” Kosseim et 
al. (2012, p.40) also added “HREA is the first legislative scheme in Canada that 
incorporates the TCPS thereby elevating its status from national guidelines into law. 
Interestingly, however, HREA also provides for the possibility that the REB may, with 
the approval of the HREA, vary a standard or rule contained in the TCPS where the 
board considers it appropriate to do so.” Although there is no specific board established 
to review benefit-sharing approval, the authorities appointed ( to the provincial ethics 
boards which administer exemption of personal health information disclosure for 
research approved by an ethics authority and flexibility of the board to employ while 
reviewing the proposals along with TCPS seems to have satisfied the academicians 





There is an ongoing private sector-driven scientific project called Newfoundland 
Genome Project, launched in August 2019, which is the one that medical ethicists, 
including Daryl Pullman, approached with caution. The project is being conducted 
by Sequence Bio, which is a St. John’s based company founded in 2013. Of the co-
founders, Chris Gardner is the CEO of the company since 2016, when former CEO 
Tyler Wish resigned. Gardner, a native of the province, studied Business at Memorial 
University while the former CEO, Wish, received his Ph.D. in medicine from Memorial 
University and is currently in cannabis business with his new company NACBio in 
Vancouver, BC.  
The company was invested by the provincial government through share 
purchase valued at $300.000 in 2015 by Venture Newfoundland and Labrador, a 
venture capital fund established by the provincial government and managed by Pelorus 
Venture Capital Ltd. to support innovative entrepreneurs with high-growth potential 
start-ups. Concerning the support of the provincial government to the start-up 
company, Darin King, Minister of Business, Tourism, Culture, and Rural Development, 
stated that (Government of Newfoundland and Labrador, News Releases, July 21, 
2015): 
“government established Venture Newfoundland and Labrador to 
support entrepreneurs and to encourage innovation and new 
business growth. Investments such as this are essential to 
fostering a more diverse economy and are a key factor in this 
government's Population Growth Strategy. I am pleased to 
celebrate today the first company to benefit from the fund, 
Sequence Bio”.  
In addition, Sequence Bio and provincial government, during the administration 
of Health and Community Services Minister Steve Kent in 2015, signed an agreement 
for looking for 100,000 people to capture genomic and phenotypic information. The 





company managed to strengthen its financial position through venture capital funding. 
According to an article in The Independent, the company attracted more than $4 million 
investment from venture capitalist firms following the agreement with the provincial 
government in 2015 (Baird, 2020). 
However, the Health Research Ethics Board (HREB) did not approve the 
proposal of the company despite governmental support. The company took HREB’s 
decision to the Supreme Court of Newfoundland and Labrador and, after the resolution 
of the Supreme Court, managed to obtain approval of HREB for the first phase of the 
project in 2019 with a limited number of participants. NL Genome Project is being 
conducted with the collaboration of family physicians, nine as of the date of the thesis. 
In this project, the saliva samples of the participants are collected with informed 
consent. The project promises to create over 100 new jobs and invest $150 million in 
the provincial economy. The company conducts the project in collaboration with the 
provincial government, as well as Memorial University, through a Master Licensing 
Agreement, according to which the University will be compensated for discoveries 
made using any of their existing data. According to Baird (2020),  the company finds a 
solution to access the data of the Newfoundland Labrador Centre for Health 
Information, which maintains health databases in the province, as this institution 
refused their data access request. 
The company has developed close connections with politicians to secure its 
position as well. For instance, Sequence Bio, according to the website of the company, 
worked with former Senator Jim Cowan to support the passage of Bill S201 enacted in 
2017 to ban genetic discrimination, which can be used against people with genetic 
dispositions for certain diseases within the context of health insurance policy 





writing, is campaigning for the leadership of the Liberal Party of Newfoundland and 
Labrador and has been a board member of the company. The case of Sequence Bio 
proves the salience of the research ethics board, which were able to reject the research 
proposal of the company and delayed the economic returns of investments into the 
company, in the governance of genetic research as projected by the provincial 
approval model, despite the collaboration of the company with the provincial 
government and venture capital investments. However, the Sequence Bio case tends 
to approach a hybrid governance model because of the partnerships with the provincial 
government, including direct investment into the company, and relations with local 
politicians. 
4.4)  Conclusion 
The development of the genetic governance mechanisms in the province 
complies with neoliberal policies to channel the local values into the market 
mechanism, including the genetic legacy of the population, thereby creating high-
technology sectors for competitiveness. Meanwhile, the governance model called 
‘provincial approval’ bears strong characteristics of communitarianism. In the benefit-
sharing principle, the community plays a crucial role, as well as expert knowledge, to 
achieve the distributive justice of benefits among community members.  
However, it is complicated to implement benefit sharing principle in genomic 
research. There are crucial points to define, including the content of basic principles. 
Ten Have (2011, pp. 320-321) mentions two problems that need clarification for the 
application of benefit-sharing. The first one is related to the boundaries of one of the 
fundamental concepts, the definition of community in this new global bioethics 





the policy-making processes, it is essential to define these concepts clearly to 
authorize the experts for the application of benefit-sharing into practice. 
The policymakers in the province applied to expert knowledge because of the 
technical nature of the issue. It is quite usual that the assistance of scientists would be 
called upon for a subject like genomics. However, what is unique in the Newfoundland 
context is the anticipated role of these experts. In the provincial approval model, 
experts are allowed to decide on the conformity of research proposals with the 
community values and distributive justice principles. In this setting, the functions 
assigned to experts in the ethics board to ensure the distributive justice of benefits 
accrued through genetic research go well beyond the meaning of the community and 
the provincial government as well, thereby resulting in an institutionalized legitimacy 
by expert knowledge.  
The communitarian perspectives focus on community values and the role of 
institutions on the individuals, in other words, in the subjectification processes. Walzer 
(1984, pp. 328-329) claims that institutional discipline, through the work of internal 
elites, professionals with claims to scientific knowledge, is exaggerated by Foucault. In 
this framework, the success of these elites, and their ability to sustain their discipline 
without state power is quite limited. If the focus of communitarian critiques on neoliberal 
policies were on the homogenizing impact of those policies on individuals as a tool of 
uncoercive oppression, their arguments and the models influenced by them would be 
much more helpful. However, they affirm institutions that discipline individuals to create 
docile bodies, as Foucault pointed out, it seems to ignore the subjectification processes 
and power relations for the sake of the shared values of the community. It is not a 
logical conclusion that a community can cure its own diseases within it through 





creates an inadequate analysis, just as the ones that rely on the individual autonomy 





CHAPTER FIVE: CONCLUSION 
5.1) Overview 
This chapter will summarize how genomic governance mechanisms are shaped 
by political and economic factors, and function to create alternative discourses based 
on cases illustrated in previous chapters. In parallel with the political-economic 
transformation of welfare states under neoliberalism, changes at the governmental 
level also appeared. This is the “emergence of a range of rationalities and techniques 
through regulated choices made by discrete and autonomous actors” (Rose, 1996, p. 
328). New techniques of governance aim to link personal conduct with socio-political 
objectives at the macro level creating regulated freedom for subjects (Miller & Rose, 
1993). In this sense, “‘biopolitics’’ signifies from the start a conceptual complexity that 
is in keeping with real tensions between the simultaneous promotion of individual 
freedom and the justification of coercive strategies in liberal societies” (Raman & 
Tutton, 2010, p. 716). Whereas emphasizing the autonomous -rational subject, a new 
mode of governance also creates alternative discourses that coexist with governmental 
techniques to convince individuals that they pursue their interests as well.  
The neoliberal model reshaped public services towards the targets of 
privatization and marketization. The transformations in the delivery of public services 
led to alterations in the rationality and practices of governance. ”As an assemblage of 
governmental practices, public health not only through state-directed regulatory 
strategies but also by invoking individuals’ desires to regulate their own conduct in the 
name of health“ (Polzer, 2005, p. 80). In this setting, the notion of patient empowerment 
functions to canalize the conduct of individuals in parallel with the targets of a privatized 
health care system while convincing them they are pursuing their choices. 





the key elements of new techniques of health promotion focusing on the preventive 
measures (Petersen, 1996). This understanding of health promotion addressing self-
rationality and self-regulation is in parallel with the controlled freedom of subjects under 
neoliberalism. Empowered subjects live this environment of freedom as consumers of 
genetics-based diagnostic products and personalized therapies. “Patients actively 
engage with the production, interpretation, and enactment of health data and involve 
in clinical decision-making through digital health technologies as well” (Petrakakia et 
al., 2018, p. 150). The freedom of subjects through the entrepreneur-consumer role is 
also strengthened with opportunities because of the increasing health technologies 
market. Individuals can invest in biotechnology and pharmaceutical companies that 
discover new diagnostic and therapeutic products to render medicine more precise, 
therefore shaping the policy-making in this field. Even the function of expertise 
changed under the neoliberal shift. “The authority of expertise detached from the 
apparatuses of political rule is relocated within a market governed by the rationalities 
of competition, accountability and consumer demand” (Rose, 1993, p. 285).  The 
privatization and marketization of public services under the neoliberal model create a 
discourse based on the dominance of the free market as a regulatory basis of activities, 
therefore encouraging consumer-entrepreneurship and academy-industry 
collaborations.  
In brief, biotechnology companies, venture capital investors, and governments 
play significant roles in the emergence and support of biotech industry, including 
genomic research activities and biobanks. Discourses of rational self-interest and 
personal responsibility are deployed by those parties; in particular cases, national 





parallel with neoliberal governance model. These discourses mask not only ethical 
concerns but also power relations between the parties.  
5.2) Evaluation of Case Studies  
The cases examined in the previous chapters have been highly influential in the 
discussion about the governance of genomics. Issues of presumed consent and 
executive rights of a private company to the comprehensive database, which includes 
not only the genetic profiles of the current population but also links ten generations of 
Icelanders, have been discussed worldwide even after the debates on HSD as well. 
According to Andorno (2016, pp. 29-30), the Icelandic database is not compatible with 
European Directive 95/46, which regulates data protection on the basis of informed 
consent for personally identifiable information and the World Medical Association 
critiques Iceland in its declarations in 2002 as well.  
The Icelandic experience also provides lessons to other countries attempting to 
construct similar databases. ”The difficulties in developing the Iceland biobank 
probably prompted the UK Biobank’s extensive efforts to connect social groups and 
civil society organizations with the biobank” (Gottweis & Lauss, 2012, p. 70). 
“Proponents have emphasized the open and democratic nature of the project – 
voluntary participation, feedback and communication – and its commitment to the 
public good. There is an evident attempt to distance the project from the Icelandic 
Health Sector Database that was the focus of much critical attention and to help dispel 
any concerns that people might have about coercion, commercial profiteering and the 
improper use of information “ (Petersen, 2005, p. 286). For Rose (2001, p. 123), in 
addition to scientific-academic debates, global players in the pharmaceutical industry, 
such as Smith Kline Beecham (GlaxoSmithKline), developed more cautious 





to work slowly and consensually to include all parties, contrary to the market-driven 
approach of the Icelandic case.  
The benefit-sharing provincial approval model developed for Newfoundland and 
Labrador was echoed during the debates for the Scottish Biobank. Haddow et al. 
(2007, p. 279) endorse this model, which they claim is “applicable to other contexts of 
benefit-sharing, although designed to take account of the specific historical–political-
economic circumstances of Newfoundland and Labrador.” As can be seen, both cases 
aforementioned have specific implications on the debates of the governance of genetic 
research. The salience of these places goes beyond being homogenous populations, 
which is advantageous to research the genetic roots of the diseases in that the 
practices and theoretical perspectives to govern the research activities encompass the 
particular responses of the parties involved and political-economic factors. 
Economic advantages to local economies through investments into the genetic 
pool of Iceland and Newfoundland are the main factor that motivates actors residing in 
these places. In fact, both of the cases were “quasi-peripheral populations” within the 
global core when new genetics came into prominence globally in the late 1990s. The 
geographic isolation and the economic crises of local economies, which were hit hard 
by the decrease in the fishery sector in the North Atlantic, were the main factors 
rendering new economic development strategies more attractive in both cases. In this 
sense, the contribution to local economies played a crucial role in recognition of genetic 
endeavors in these regions. For instance, the “Icelandic project emphasizes the 
opportunities of medical advances, work, entrepreneurship, and private initiative, in the 
age of the challenging new economy and stagnant or declining fishing stocks 
“(Gottweis & Zatloukal, 2007, p. 209). There were direct referrals to the benefits of the 





“Policy implications of commercial human genetic research in Newfoundland and 
Labrador“ (2003, p. 3), infrastructure could be developed, the province is research-
capacity enhanced, and the provincial economy is stimulated as a result of genetic 
research conducted in the province. These promises not only addressed what states 
are searching for, maintaining their national competitiveness under the neoliberal 
model and knowledge-based economy. At the individual level, economic benefits 
promised were also welcomed in that the initiatives that promise the benefits of new 
employment opportunities through foreign investment converged with macro targets of 
the state. 
The structure of genetic research projects is, in essence, similar in both cases. 
In Iceland, the genomic project was established as an entrepreneurial model based on 
the partnership with the state but self-funding by the private sector (Gottweis & Lauss, 
2012). deCODE Genetics was founded with capital provided by venture capitalist firms 
and funded genetic research in the country by way of further capital gains as a result 
of the public offering of its shares. In Newfoundland, the first genomic enterprise, 
Newfound Genomics, was established as a private sector joint-venture to be funded 
by the British biotechnology company and a local company of physicians. However, in 
both cases, the state has been an important actor in the proceedings of the events. In 
Iceland, deCODE was able to get an exclusive license, which was granted by a 
particular law, to establish and operate the health sector database because of state 
support to the project. In Newfoundland, Newfound Genomics was given loans by a 
state development agency to survive the economic crisis, whereas Sequence Bio, the 
owner of an ongoing genetic project, was able to get direct investment by the state 





The state plays a central role in coordinating and steering biopolitics, like its 
function in the nineteenth century (Gottweis, 2008, p. 24). The involvement of state 
actors as facilitators of these genetic projects complies with the “governmentalization 
of the state” notion according to which the limits and survival of the state can only be 
understood on the basis of general tactics of governmentality (Foucault, 1991, p. 103). 
Neoliberalism represents a complex and contradictory assemblage, policies, practices, 
and discourses rather than being an organic and consistent entity (Ylönen, 2016, p. 3). 
Under the neoliberal model, the governmentalized state again coordinates and steers 
the projects of genetic databases, which is the contemporary biopolitical project, 
through these complex techniques and discourses that coexist and mobilize individual 
conduct in line with particular political-economic ends. 
Discourses about national values and uniqueness that deserve to be protected 
prevail in both cases. However, it has a more distinctive form in the Icelandic genome 
project. The private sector company succeeded in articulating its for-profit targets with 
national values, such as Icelandic people’s enthusiasm for genealogical records. The 
company deployed the rhetoric of national value to convince individuals that the genetic 
project contributes to nation preserving their genetic heritage with technological 
facilities. Pálsson (2007, pp. 98-101) claims that “nationalist discourse” of “Icelandic 
sagas, glories of the past, the uniqueness of Icelandic heritage and interest in Nordic 
gene” is consistent with constructing a comprehensive database, which is an old dream 
to be realized with “modern bioinformatics and computer technology,” even stated by 
Halldor Laxness during World War II, a prominent author figure of Icelandic identity. In 
this sense, the Icelandic model is constructed on the identity-making and cultural 
symbols around the Nordic culture in as well as economic benefits to the country. The 





in clause in HSD, were assured that their contribution would serve for the preservation 
of culture and its traditions that Icelandic people belong to and proud of. As Petersen 
(2005, p. 284) points out, “the notions like altruistic, gift, sharing, opportunities to help 
others, common interest, help those suffering from the disease have a strong 
resonance with an emphasis on the mutuality of interest. “ In fact, “the construction of 
genetic databases will be driven by demand from the commercial sector and the 
altruistic or scenario benefits will directly accrue to commercial enterprises, to some 
extent to the population, but not to sample donors” (Williams & Schroder, 2004, p. 95). 
The nationalist discourse was frequently deployed during the Icelandic genome project, 
which functioned to mask the actual beneficiary of this enterprise. 
 The benefit-sharing principle has been a more active element of the model 
developed in Newfoundland as compared to the Icelandic genome project. In some 
accounts, the promise of Hoffman-LaRoche for free drugs to Icelandic people within 
the context of the company’s collaboration with deCODE comply with the benefit-
sharing principle. For instance, Knoppers (2000, p. 213) claims that contractual 
arrangements in Iceland, according to which Icelandic people would be given free 
products, tests, or drugs if they were discovered as a result of the project, is an example 
of the “ efforts to recognize the equitable nature of benefit sharing.” Lucas et al. ( 2013, 
pp.100- 101) point out a different perspective in that deCODE’s database would allow 
Roche to track the effectiveness and side effects of products easily in Iceland before 
post-marketing (Phase IV) trials and exemplifies an argument made by Ernir 
Snorrason, who left deCODE because of his concerns, in a letter to the parliamentary 
committee on HSD Bill supporting Roche’s drug testing intentions on Icelanders. 
Contrary to the blurred interpretation of the benefit-sharing principle in Iceland, 





upon this principle. The provincial approval model was constructed upon the principle 
of benefit-sharing in parallel with the HUGO Ethics Committee recommendation 
supporting moral principles of justice and solidarity (Pullman & Latus, 2003, p. 543). 
The principle of solidarity stated by the HUGO is in parallel with communitarian 
discourses, even if its reconciliation with the focus on justice in exchange might be 
difficult (Andanda et al., 2013, p. 55). The Policy Implications of Commercial Human 
Genetic Research in Newfoundland and Labrador Report (2003), authored by the 
same academicians, emphasize the just and equitable distribution of the benefits and 
burdens among all parties involved in genetic research as well as protection of local 
communities. The distributive justice accompanied by solidarity in genetic research in 
the province will be approved and observed by Standing Committee on Human Genetic 
Research within ethics board, which will be composed of experts in genetics, medicine, 
pharmacology, business, law, health policy, and medical ethics according to the same 
report. In practice, the committee as a part of ethics boards with such comprehensive 
authorities was not implemented. However, the provincial ethics board has been 
decisive on the evaluation of the research project proposals as projected. For instance, 
Sequence Bio, a local biotechnology company in which the provincial government 
invested as well, was not able to get the approval for the genome project in the province 
until they appealed the decision of the ethics board in the Supreme Court. Although 
the Icelandic National Bioethics Committee functions similarly, the changes in the 
appointment of the members of the committee during the Icelandic genome project 
enabled politicians to intervene in the activities of this board. 
 The position of experts is the main point of departure between the two genomic 
research projects. Whereas the experts in Newfoundland have been actively involved 





the experts in the early phases of the HSD Bill. The provincial government recruited 
medical experts to make reports and recommendations about the governance of 
genetic research following the increasing interest in the province in the early 2000s. 
Pullman and Latus (2003, p. 543) highlighted outside researchers who conduct studies 
in the province without informing local research and clinical communities, therefore 
resulting in harmful studies to the province. Their efforts to offer policy alternatives to 
govern research interest into the gene pool of the province strengthened the functions 
of the local researchers. In the Icelandic case, experts, physicians, and academicians 
were opposed to the HSD after the legislative bill was submitted and known by the 
public. Pálsson (2008, p. 42) defines the efforts of Icelandic experts against the project 
as biopolitics of the dispossessed, the strategies of those who feared to lose their 
dominance on medical practices. However, dispossession is one of the crucial notions 
to understand how neoliberalism functions. The reversion of common property rights 
(the right to a state pension, to welfare, to national healthcare) to the private domain 
has been one of the most egregious policies of dispossession pursued in the name of 
neoliberal orthodoxy (Harvey, 2003, p. 148). 
 The involvement of the patients and advocacy groups for patients is very limited 
in both cases. In the Icelandic genome project, to mention the inclusion of research 
participants into the debate is only possible as figures that opted out of the database 
because of the efforts of Mannvernd to encourage people to do so (Fortun, 2008, p. 
142). However, the direct involvement of individual research subjects into the course 
of events was highly decisive in the future of the project. The Icelandic Supreme Court 
decision on the breach of personal privacy by the HSD was a consequence of the 
appeal of an individual. In the Newfoundland case, the names of individual research 





cases with a bad reputation, such as the research of Baylor University in the province. 
However, the high prevalence of particular diseases and the research activities of 
private enterprises to find remedies for these diseases were emphasized frequently, 
for instance, deCODE’s ongoing research on twelve common diseases (Pálsson & 
Rabinow, 2001) and the high frequency of cardiovascular disease, diabetes, obesity 
and psoriasis in NL (Policy Implications of Commercial Human Genetic Research in 
Newfoundland and Labrador Report, 2003). In particular, the background of main 
figures of genomic projects working with patients in the research on locals was 
highlighted during the projects, such as Stefansson’s effort for the multiple sclerosis 
patients (Rose, 2001) and Gulliver’s previous research on psoriasis in the province 
(Pullman & Latus, 2003). In these projects, people of both places were portrayed as 
those who were willing to take part in the projects to be able to provide researchers 
with health data to mine, even though they were not able to get direct benefits for 
themselves, except indirect benefits through the contribution of projects into local 
economies which were advertised in both cases at the beginning of the projects.  
5.3) Discussion 
The subjectification processes, through which research subjects take part in the 
projects, prove that these case studies function as biopolitical projects. Under the 
neoliberal model that reorganizes activities and actors around the ethics of 
entrepreneurship, the strategies and techniques of new biopolitical projects shape 
themselves in compliance with the changing roles of state, private sector, experts, and 
individuals. If the research subjects and patients with diseases of high prevalence had 
been included in the debates, would these genomic research projects have been more 





model to be shaped by the direct involvement of patients’ groups and research subjects 
into the debates?  
As Rabeharisoa and Callon (2002, p.64), this involvement can generate a third 
way, besides government and private sector driven research projects, which has a 
capacity of production and dissemination of knowledge and expertise in an alternative 
way. Instead of automatically opting people into databases and presupposing their 
participation as voluntary ones, informing them about the details of the projects is likely 
to create different opinions and attitudes towards the research.  As Gottweis et al. 
(2011) claim public is not a fixed body of individuals, as phantom public, who are 
interested in an affair at stake and neither the time nor the interest to involve in the 
participatory structures of biobanks. However, people would have preferences about 
the goals, transparency, consent forms and, modes of operation if they are given 
information about them.  
 It is possible to multiply questions and assumptions to include other actors such 
as state and experts. Without the neoliberal shift, it is likely that states would respond 
differently to genetic research projects that challenge their sovereignty on their 
population by entailing private sector companies property rights on the discoveries 
using the gene pools of nations. How would experts have acted in the Newfoundland 
case if they had been excluded from the database debates at the beginning? Would 
Mannvernd have been established to oppose the project if the Icelandic physicians had 
been able to express their opinions adequately before the enactment of the HSD? 
Would it have been possible to propose a model to redistribute the benefits of a 
research project into a community if the members of that community had not accepted 





If knowledge generation through genomics had included the experiences of 
patients, would the costly genetic tests, which are not covered by public health 
systems, including prenatal screenings, have maintained their salience on predictions 
about genetic conditions? While these tests rely on the mining of the existing clinical 
data and patients taking the tests contribute to data, the costs which are not covered 
by public health systems are still charged directly to the patients. The case studies also 
show how nations, even if they are part of the Western world, are fragile against the 
projects aiming at the generation of value using their genetic profile considering the 
power of venture capital investments to convince the governments of the distressed 
economies to support their projects. In both cases, the mobilization of individual 
conduct in parallel with macroeconomic targets is observed even if there is no direct 
benefit for the research subjects. The promissory feature of genetics, combined with 
the ability of the neoliberal model to mask the discourses about the real beneficiaries, 
succeeds in the completion of genetic research and databases. Similar projects 
targeting periphery countries with very limited transparency on governance models and 
wider economic inequalities are likely to result in considerable damages to vulnerable 
populations.  
Knowledge generated through genetic research is highly complex and requires 
expert interpretation to decide among therapy alternatives. Technical complexity is one 
of the greatest obstacles to translating genomics into public health practices and 
extend the application of personalized medicine through empowered patients. Most 
physicians have limited knowledge of genetics and are, therefore, not equipped to 
provide genetic counseling and testing (Matlof & Caplan, 2008, 6). On the patient side, 
there is also an urgent need for genetic testing. However, the gap between genetic 





considering the social determinants of health. Racialized groups, ethnic minorities and 
adults with limited educational attainment have lower than average health literacy 
about genetics. This limited health literacy poses a particular challenge for effective 
communication with patients ( Lea et al., 2011, 282). The inadequacy in the level of 
health literacy and numeracy through its social aspects necessitates public policies in 
this field beyond the mere articulation of health with the neoliberal discourse of -rational 
and empowered individuals.  
There are contesting views regarding the governance of the genomics field to 
be addressed by policy-makers. Additionally, it is not a matter of preference. The 
hybridization of private and public and the trend towards personalized medicine, which 
is an integral part of genomic research, force public authorities to design policy 
alternatives to govern this realm. The public health and policy-making processes could 
benefit from genetic knowledge insofar as the alternative ways of knowledge 
generation are included in policy-making. For instance, the inclusion of subjunctive 
bodily experiences, and historically and geographically created meanings of health and 
illness instead of a genetic reductionist perspective generate advantages in these 
processes (Shostak, 2003, p. 2238). The policy-making decisions on genomics have 
the opportunities to find an equilibrium between the targets of economic development 
and public health outcomes, the empowered subjects, and the multitude of individuals 
amid the socially-constructed discourses. 
5.4) Contributions on Literature and Future Research 
This research examined the ends embedded in genomic projects, the 
expectations of the parties involved, and the discourses to mobilize individuals towards 
the anticipated ends, through a governmental analysis. Besides the analysis of micro-





ends in the genomics field, the neoliberal discourses of –rational individuals, and 
knowledge-based growth are described. The combination of these two levels provides 
more insightful analysis because states and international governance bodies apply the 
techniques and strategies, which are shaped by existing political-economic conjecture, 
to reach the political-economic targets. The governmentalized state shapes the 
discourses and is influenced by political-economic conjecture itself. The analysis of the 
governance of genomic research projects and genetic databases associated with them 
requires adequate considerations of the subjectification processes and multi-level 
factors, including state, private sector enterprises, as the cases in this research 
illustrate. In this sense, this thesis benefits from Foucault, neo-Foucauldians, who 
examine the micro-power relations within genomics, and also from state theory and 
political economy.  
Future research, which will use this multi-level approach, into other sectors of 
biotechnology, might provide fruitful analyses about the discourses embedded in the 
similar genetic research projects, as well as new value creation processes. Whereas 
this research focuses on the cases in the Western World, the research into periphery 
countries, with homogenous populations, is likely to produce compelling results to 
discover alternative discourses and subjectification processes. The cases in this 
research suggest that nations and governance alternatives are fragile when they seek 
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Biobanking: Biobanking describes the efforts in a legal and technological sense to 
construct biobanks that are the centers of biological samples and data collected 
through actual medical research and/or archive work (p. 63).    
Bioeconomy: Bioeconomy stands for the deployment of biotechnology to produce 
goods and services for economic value. The industries that use biotechnological 
processes, such as pharmaceuticals, food, and energy sectors, are the parts of 
bioeconomy in general (pp. 7, 37, 44, 45). 
Bioinformatics: Bioinformatics is a combination of biology and information 
technologies which provides data mining tools for the biological data. Within the context 
of the thesis, this interdisciplinary field indicates the means to crossmatch the 
components of the Icelandic genome project database (p. 101).    
Biosociality: Biosociality describes the formation of the new group and individual 
identities between health and illness, such as carriers of genetic susceptibilities as a  
result of new techniques biotechnology (p. 8).       
Biotechnology:  Biotechnology or biotechnology industry represent the application of 
the discoveries of molecular biology to develop new techniques and technologies to 
create biological processes artificially or multiply them in vitro environment ( pp. 1, 3, 
7-9, 15, 20, 21, 23, 25, 28, 29, 31, 34- 41, 44, 48, 49, 52, 59, 61, 71, 73, 75, 77, 79, 
82, 97, 100, 103, 109). 
Biovalue: Biovalue refers to the yield of vitality produced by the biotechnical 





Gene Hunters: “ Gene Hunters” describes the endeavors to discover the population 
and geographies, especially homogenous populations, which are convenient to 
research the genetic roots of the diseases (p. 83).       
Genetic Discrimination: Genetic discrimination stands for discriminative practices 
against people with genetic dispositions for certain diseases (p. 93).       
Genome Sequencing: Genome sequencing means a detailed analysis of the DNA, 
whereas whole-genome sequencing is an analysis of all genomes in an organism. 
Within the context of this thesis, population-based genomic research, such as in the 
Icelandic genome project, aims at whole-genome sequencing (pp. 5, 37, 39, 77). 
Genomics: Genomics as a branch of molecular biology research a genome, which is 
basically a complete set of DNAs ( pp. 1, 2, 4, 7, 9-11, 17-23, 27, 28, 31, 35-39, 45-50, 
69, 70, 72, 75, 77-79, 83, 85, 89, 95, 98, 107-109). 
Genotypes: Genotypes stand for the genetically inherited traits that individuals get 
from their ancestors. Genotypes are decisive in the genetically inherited diseases in 
particular ( p. 13). 
Hybridization: Hybridization or hybrid policies represent the governance model 
through a partnership between the public and private sectors as a result of the 
transformation of state. Hybridization, in this sense, stands for the extension of the 
state function through policies conducted with private sector partnerships, as well as 
the growing capacity of the opinion-making of this new political-economic setting ( pp. 
16, 17, 19, 20, 41, 108). 
 
 
 
